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MicroRNAs (miRNAs) are endogenous non-coding RNAs involved in the process 
of silencing gene expression. The mature miRNAs of 20-24 nucleotides direct the RNA-
induced silencing complex (RISC) to silence the expression of their complement target 
mRNAs. To date, more than 850 different miRNAs have been discovered in humans. In 
various human cancers, specific miRNAs were found to be differentially expressed. 
Some of the over-expressed miRNAs have been found to target tumor suppressors, and 
some deleted or down-regulated miRNAs have been found to target anti-apoptotic or 
proliferative genes. Emerging evidences suggest that changes in miRNA levels in tumors 
also affect cell division cycle-related targets, hence contributing to tumorigenesis.  
In this study, the change in the expression of 339 miRNAs during the progression 
of cell cycle of HuH7 and HepG2 cells was examined. More than 100 different miRNAs 
were identified to be differentially expressed. These miRNAs are specifically up- or 
down-regulated at G1, S or G2/M phase. Among the miRNAs that are differentially 
expressed during the cell cycle, miR-193a and miR-210 were found to be up-regulated in 
HuH7 cells during the G2/M phase. These two miRNAs were also found to decrease cell 
proliferation by delaying cell cycle progression. Upon further analysis, Yes1, a member 
of the Src family of non-receptor tyrosine kinases, was found to be a target of miR-210. 
The knockdown of Yes1 by siRNA also produced a similar decrease in cell proliferation. 
Hence, the up-regulation of miR-210 in G2/M phase caused the silencing of Yes1 
expression at the G2/M phase, and Yes1 might serve to relay mitogenic signals and result 
in promoting cell cycle progression in the G1 and S phases. miR-122a, miR-96 and miR-
107 were also found to cause changes in cell proliferation.  
 vi 
In summary, this study indicates that some miRNAs are differentially expressed 
across the cell cycle phases, and a subset of these miRNAs could play different roles in 
the regulation of cell cycle by repressing the translation of cell cycle-related targets. 
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1.1 RNA INTERFERENCE 
 
Gene expression has been known to be primarily controlled at the level of 
transcription initiation, and secondary systems of control include RNA turnover, RNA 
processing and translation, and at the level of protein maturation, modification and 
degradation. In recent years, research in the post-transcriptional level of gene silencing 
has developed greatly with the discovery of the phenomenon called RNA interference. 
RNA interference refers to a process of silencing of gene expression, in which the 
terminal effector molecule is a small 20-24 nucleotide antisense RNA (Scherer and Rossi, 
2003). This system acts like a censor, to intercept the expression of high amounts of 
particular target messenger RNA (mRNA) complementary to the effector molecule and 
shredding the target mRNA, such that the expression of that particular mRNA is tightly 
controlled. It was first discovered in plants in 1990, when two groups over-expressed a 
pigment synthesis enzyme in order to produce deep purple petunia flowers, but it resulted 
in co-suppression of the transgenic and endogenous genes, generating predominantly 
white flowers (Napoli et al, 1990; van der Krol et al, 1990). In 1998, Andrew Fire and 
Craig Mello published their work on double-stranded RNA causing the reduction of 
homologous target mRNA levels in Caenorhabditis elegans and this effect was not 
achieved by antisense or sense RNA (Fire et al, 1998; Montgomery et al, 1998). The 
ability of double-stranded RNA to post-transcriptionally silence the expression of a gene 
bearing a sequence highly homologous to its own sequence was termed RNA interference. 
This has been found to be very important in protecting cells from hostile genes and to 
regulate the activity of normal genes during growth and development. This gene-
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censoring mechanism is also thought to protect against viruses and mobile genetic 
elements (Lau & Bartel, 2003). RNA interference has now been applied to selectively 
target mRNA degradation with the use of small-interfering RNA (siRNA), and is also 
used as a technique to investigate gene function. The same mechanism was also found 
with small RNAs endogenously encoded and produced within cells, and these small 
RNAs were termed microRNAs (miRNAs). In 2006, Fire and Mello received the Nobel 
Prize in Physiology or Medicine for their work on RNA interference.  
 
1.2 DISCOVERY OF MICRORNAS 
 
Genetic screens performed by the Ambros laboratory to characterize two genetic 
loci involved in the control of developmental timing in C. elegans uncovered a ~22-
nucleotide single-stranded non-coding RNA as the product of the lin-4 gene. Lin-4 RNA 
repressed the protein levels of lin-14, a gene that functions in the same developmental 
pathway. The lin-4 RNA had the potential to bind, with partial antisense complementarity, 
to sequences found in the 3’-untranslated region (3’-UTR) of lin-14 mRNA and repress 
its translation (Lee et al, 1993). Subsequently, another ~22nt RNA let-7, another gene 
controlling developmental timing in the worm, discovered by the Ruvkun laboratory, was 
also found to recognize sequences present in the 3’-UTR of its lin-41 mRNA target and 
repressed lin-41 protein levels; lin-4 and let-7 were named small temporal RNAs 
(Reinhart et al, 2000). These were found to be derived from longer double-stranded 
RNA-hairpin precursors and later named miRNAs. Sensitive cloning methods, combined 
with bioinformatic approaches, have since been developed to identify these endogenous 
miRNAs on a large scale (Ambros and Lee, 2004). To date, more than 850 miRNAs have 
been discovered in humans alone and registered on the Sanger registry. 
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(http://microrna.sanger.ac.uk/sequences/). They can be located in coding or non-coding 
transcripts, on exons or introns (Rodriguez et al, 2004). Some miRNAs are clustered and 
are found in close proximity to other miRNAs, for example, miR-106b, -93, -25 (Altuvia 
et al, 2005).  
Many identified miRNAs are evolutionary conserved from species to species, 
including C. elegans, mouse, rat, drosophila, and humans. miRNAs bearing sequence 
homology are classified into families, and those in the same family often have similar 
expression patterns spatially and temporally, suggesting that the targets that they regulate 
within the same family of miRNAs are similar (Lee et al, 2007). The let-7 family shows 
the most extensive conservation among all metazoans (Chen et al, 2005). Based on such 
conservation characteristics observed in stems of miRNA hairpins, this characteristic 
profile has been used to predict novel miRNAs using cross-species comparisons 
(Berezikov et al, 2005). 
 
1.3 BIOGENESIS OF miRNAs 
 
Endogenous miRNA genes are transcribed mainly by RNA polymerase II (pol II) 
to generate the primary transcripts (pri-miRNAs) (Lee et al, 2004) (Figure 1.1). The pri-
miRNAs contain 5’ cap structures as well as 3’ poly(A) tails, with stem-loop secondary 
structures bearing the sequence of the mature miRNA, and they can be several kilobases 
long if they are transcribed within a protein-coding transcript or if the individual miRNAs 
are clustered together and transcribed as a single polycistronic primary transcript (Cai et 
al, 2004). For example, a miR-106b-93-25 cluster is embedded in the thirteenth intron of 
DNA replication licensing factor MCM7 transcript (Rodriguez et al, 2004).  
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Figure 1.1. Biogenesis of miRNA from gene to mature form. The red strand represents 
















The pri-miRNAs generated are processed in the nucleus by the microprocessor 
complex Drosha with co-factor DiGeorge Syndrome Critical Region gene 8 (DGCR8) 
(also known as Pasha in Drosophila and C. elegans). DGCR8 bears the RNA-binding 
domain and recognizes the distinct stem-loop structure and binds to the pri-miRNAs. 
Drosha (a RNase III endonuclease) then crops the pri-miRNA at the base of the stem-
loop into precursor miRNAs (pre-miRNAs), a stem-loop of about 60-100 nucleotides 
with a 2-nucleotide 3’ overhang (Han et al, 2004). In animals, pre-miRNAs are exported 
from nucleus to cytoplasm by exportin-5, with GTP-binding co-factor Ran (Bohnsack et 
al, 2004). Once in the cytoplasm, pre-miRNAs are processed by Dicer (an RNase III 
family member), releasing a 20-24 nucleotide miRNA-miRNA duplex, which has a two 
base overhang at both 3’ ends (Hutvagner et al, 2001). This product is not very stable, 
and usually only one strand of the duplex is incorporated into RNA-induced silencing 
complex (RISC) as the mature miRNA while the other strand is degraded. From studies 
with siRNA, it was found that the strand with relatively unstable base pairs at the 5’ end 
is selected and incorporated into the RISC (Schwarz et al, 2003; Khvorova et al, 2003). 
In D. melanogaster, the more stable strand is bound by R2D2, the fly cofactor for Dicer-2 
(Tomari et al, 2004). 
 
1.4 MECHANISM OF ACTION OF miRNAs 
 
Mature miRNAs are incorporated into RISC and they direct the RISC to their 
targets to down-regulate gene expression, either by mRNA cleavage or translational 
repression. In plants, most known mRNAs that are silenced by miRNAs are perfectly 
complementary to the corresponding miRNA, and their complementary sites are located 
throughout the transcribed regions of the target gene (Rhoades et al, 2002). The miRNA-
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target interaction usually induces mRNA cleavage catalyzed by RISC at the site where 
the miRNA resides. In contrast, most known mRNA targets in animals are only partially 
complementary to their corresponding miRNAs at the 3’UTR of the mRNA. A few 
animal miRNAs have perfect or near-perfect complementarity to the target mRNA, which 
allows the mRNA to be sliced between 10 and 11 nucleotides from the 5’ end of the 
miRNA (Yekta et al, 2004). In the case of partial complementarity, a ‘seed match’ of 
positions 2 to 7 nucleotides at the 5’ end of the miRNA determines the target sequence to 
be bound to itself, and the 3’ end of the miRNA subsequently ‘zipper-up’ with its target 
(Lewis et al, 2005).  
Recent studies on the components of the RISC have shed more light on the 
process of miRNA-mediated translational repression. RISC consists mainly of the core 
protein Argonaute (Hammond et al, 2001; Liu et al, 2004). Argonaute proteins contain 
two RNA-binding domains: the Piwi domain, which binds the small RNA guide at its 5’ 
end, and the PAZ domain, which binds the single-stranded 3’ end of small RNA. The 
endonuclease that cleaves target RNAs resides in the Piwi domain, and this domain is a 
structural homolog of the DNA-guided RNA endonuclease RNase H (Song et al, 2004). 
Other components of RISC include the general translation repression protein RCK (also 
known as p54) (Chu et al, 2006), and GW182 (Liu et al, 2005). Recent studies have 
shown that small RNAs, bound to Ago2 (an Argonaute protein), can move the mRNAs 
they bind from the cytosol to P-bodies which are cytoplasmic foci that contain 
translationally repressed mRNA-protein complexes (Liu et al, 2005; Sen et al, 2005). 
Multiple copies of the miRNA-mRNA-RISC that contains RCK/p54 could initiate an 
oligomerization event that sequesters the whole ribonucleoprotein particle that transports 
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it to P-bodies. Once in P-bodies, translationally repressed mRNA could stay in 
oligomeric structures for storage or could form a complex with decapping enzymes 
Dcp1/2, removing the 7-methyl guanosine cap, triggering its destruction by the 5’ to 3’ 
exonuclease Xrn1 (Zamore and Haley, 2005). Furthermore, Ago proteins contain a highly 
conserved motif that shows similarity to the 5’methyl-guanine cap-binding motif of the 
translation initiation factor eIF4E. In the absence of the miRNA-RISC complex on the 
specific mRNA, eIF4E recognizes and binds to 5’methyl-guanine cap of the mRNA. 
eIF4G binds to both the eIF4E and the poly(A) binding protein and therefore allows the 
establishment of a closed loop, which is required for efficient translation initiation. Upon 
the miRNA-RISC complex binding to the 3’UTR of the specific mRNA, Ago proteins 
compete with eIF4E for cap binding. The interaction of Ago with the cap releases 
eIF4E/G and inhibits translation initiation (Kiriakidou et al, 2007). In contrast, 
Chendrimada et al. identified the association of Ago2 with eIF6, an anti-translation 
initiation factor involved in the biogenesis and maturation 60S ribosomal subunits and 
which also prevents their premature association with the small 40S subunits, such that the 
recruitment of eIF6 by Ago2 may repress translation by preventing the assembly of the 
translationally competent 80S ribosomes (Chendrimada et al, 2007). A study on D. 
melanogaster cells however showed that eIF6 was not required for silencing, but that 
Ago1 (the Argonaute protein that mediates miRNA function in D. melanogaster) binds to 
both the 5’ methyl-guanine cap of mRNA and GW182 for silencing and localizing the 
miRNA-mRNA-RISC to P-bodies (Eulalio et al, 2008). 
In addition to repressing translation, animal miRNAs can also induce degradation 
of target mRNAs (Bagga et al, 2005; Behm-Ansmant et al, 2006; Wu et al, 2006). 
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Studies in zebrafish embryos, D. melanogaster and human cells showed that miRNAs 
accelerate deadenylation of their targets by having the RISC to recruit components of the 
general mRNA degradation machinery (Giraldez et al, 2006; Behm-Ansmant et al, 2006; 
Wu et al, 2006).  
 
1.5 REGULATION OF miRNA EXPRESSION 
 
How miRNAs are regulated is not clear. Bioinformatic searches for miRNA-
specific promoter elements, transcription factor binding sites and cis-regulatoy motifs 
that are upstream of miRNA sequences are still being studied (Lee et al, 2007). For 
miRNAs that are transcribed within a protein-coding transcript, the ‘host’transcript and 
miRNAs usually have similar expression profiles. Only a few promoters of miRNAs have 
been identified experimentally, and very few mammalian transcription factors that 
regulate miRNAs have been identified. The promoter for the miR-23a-27a-24-2 cluster 
expressed on a non-coding transcript had no known common promoter elements that are 
required for transcription initiation complex, including the TATA box, the initiator 
element, the downstream promoter element or the TFIIB recognition element. The only 
exception was the GC boxes that, when deleted, resulted in a moderate reduction in the 
expression of the cluster (Smale and Kadonaga, 2003).  
Recently, it has been found that c-Myc, which encodes a transcription factor E2F1 
that regulates cell proliferation, activates expression of a cluster of six miRNAs on 
human chromosome 13 (O’Donnell et al, 2005). Upon further study of the promoter 
region of this miR-17 – 92 cluster, two functional E2F transcription factor binding sites 
were found, and E2F3 was the primary E2F family member that promotes the expression 
of the miR-17 – 92 cluster (Woods et al, 2007). Similarly, miR-132 was identified to be 
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regulated by cAMP-response element binding protein in neurotrophins, with the CRE 
consensus sequence found upstream of the miRNA (Vo et al, 2005). miR-127 was found 
to be highly induced in cancer cells after treatment with chromatin-modifying drugs 5-
aza-2’-deoxycytidine and 4-phenylbuytric acid, which inhibit DNA methylation and 
histone deacetylase. This study suggested that miRNAs could be regulated by epigenetic 
alterations (Saito et al, 2006). p53 has also been found to target miR-34b and miR-34c 
and these two miRNAs cooperate in suppressing proliferation and soft-agar colony 
formation of neoplastic epithelial ovarian cells, showing the existence of a novel 
mechanism by which p53 suppresses such critical components of neoplastic growth as 
cell proliferation and adhesion-independent colony formation (Corney et al, 2007). A 
major transcription factor that responds to hypoxia (decreases in the oxygen 
concentration) is the hypoxia-inducible factor (HIF), and hypoxic induction of miRNAs 
have been documented, with miR-210 being the most highly up-regulated (Hua et al, 
2006; Donker et al, 2007; Kulshreshtha et al, 2007; Fasanaro et al, 2008; Kulshreshtha et 
al, 2008). 
Many miRNAs have tissue-specific or developmental stage-specific expression, 
suggesting they are involved in developmental processes. Furthermore, the spatial and 
temporal expressions of miRNAs have been reported to be antagonistic to the expression 
of their targets (Stark et al, 2005). The C.elegans let-7 has been found to be 
transcriptionally controlled by the temporal regulatory element (TRE) situated about 
1200 base pairs upstream of the mature let-7 RNA. Together with the TRE binding factor, 
the nuclear hormone receptor DAF-12 and the RNA binding protein LIN-28, they 
regulate the expression of let-7, allowing it to be robustly expressed during the fourth 
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larval and adult stages (Johnson et al, 2003). Muscle-specific miRNAs miR-1 and miR-
206 have also been demonstrated to be regulated by myogenic factors myogenin and 
myogenic differentiation 1, suggesting that the induction of these miRNAs is important in 
regulating the expression of muscle-specific proteins (Rao et al, 2006).  
 
1.6 TARGETS OF miRNAs 
 
Mammalian miRNA targets have been difficult to identify due to the partial 
complementary base pairing between the miRNAs and their target sequences. There have 
been many studies done on computational target prediction, which rely on sequence 
complementarity between the miRNA and the putative target sequence at the 3’-UTR, 
conservation of target sequences in related genomes, and free energy of binding between 
the miRNA and its putative targets (John et al, 2004; Lewis et al, 2005). Commonly used 
prediction programs are listed in Table 1.1. 
 
Table 1.1. Methods and resources for miRNA target prediction. 
Program Approach Resource Reference 
miRanda Complementarity http://www.microrna.org/ John et al, 2004 
miRanda 
miRBase 
Complementarity http://microrna.sanger.ac.uk/ Griffiths-Jones 
et al, 2006 
TargetScanS Seed 
complementarity 
http://www.targetscan.org/ Lewis et al, 
2005 
DIANAmicroT Thermodynamics http://diana.pcbi.upenn.edu/ Kiriakidou et al, 
2004 
PicTar Thermodynamics http://pictar.bio.nyu.edu/ Krek et al, 2005 








A recent study on the principles of miRNA-target recognition classified the 
miRNA target sites into three categories. In the first category, “canonical” sites have 
good base-pairings for both 5’ and 3’ ends. In the second category, “seed only” sites have 
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positions 2 to 7 nucleotiedes at the 5’ end of the miRNA perfectly complementary to the 
target sequence, requiring little or no 3’ pairing. In the third category, “3’ compensatory” 
sites have weak 5’ complementarity and depend on strong base-pairing to the 3’ end of 
miRNA (Brennecke et al, 2005). 
 
 
1.7 BIOLOGICAL FUNCTIONS OF miRNAs 
 
Prediction of the targets of miRNAs by the various algorithms can generate more 
than hundreds of possible targets, and only few targets have been experimentally 
identified. The relevance of any experimentally identified targets of miRNAs has to be 
linked to biological functions where the miRNAs and their targets are being expressed. 
As mentioned previously, the expression of the specific miRNAs and their targets tend to 
be antagonistic, with highly expressed miRNAs giving rise to low expression of the 
protein targets (Stark et al, 2005). Two major approaches to elucidate the roles of 
miRNAs are to use their expression data under biological conditions to narrow the list of 
potential miRNA targets. The other approach is to knockdown or over-express specific 
miRNAs and observe the subsequent effects (Cheng et al, 2005). 
miRNAs are essential in animal development. Mice lacking in Dicer die at 
embryonic day 7.5 and lack multipotent stem cells (Bernstein et al, 2003). In addition, 
DGCR8-deficient embryonic stem cells have compromised differentiation (Wang et al, 
2007). This suggests that embryo development needs the presence of certain miRNAs. 
HOX is an important transcription factor in animal development, and it is negatively 
regulated by miR-196 and miR-181. Knockdown of these miRNAs caused abnormal 
expression of HOX, and results in animal development abnormality (Yekta et al, 2004; 
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Naguibneva et al, 2006). Similarly, in DiGeorge Syndrome, the Drosha cofactor DGCR8 
located on chromosomal region 22q11.2 is commonly deleted. The symptoms of this rare 
congenital disease include a history of recurrent infection, heart defects, and 
characteristic facial features (Denli et al, 2004; Gregory et al, 2004; Landthaler et al, 
2004; Baldini, 2004). These evidences show that miRNAs are not only essential for 
development, but are also important in regulating the expression of many genes. 
 
 
1.7.1 miRNAs in apoptosis and metabolism 
 
Forward genetic screens in flies have led to the discovery of miRNAs involved in 
programmed cell death, or apoptosis. The bantam miRNA simultaneously stimulates cell 
proliferation and prevents apoptosis by regulating the pro-apoptotic gene hid (Brennecke 
et al, 2003). Further work on the expression of bantam showed that it is regulated by the 
transcriptional activator Yorkie in the Hippo signaling pathway, showing that bantam 
levels are regulated both during developmentally programmed proliferation arrest and 
apoptosis (Thompson and Cohen, 2006). Similarly, fly miR-14 functions as a cell death 
suppressor and is also required for normal fat metabolism (Xu et al, 2003). The steroid 
hormone receptor for Ecdysone has been experimentally identified as a target for miR-14. 
This receptor plays a key role in the control of developmental timing and metamorphosis 
and regulates adult physiology and lifespan. Ecdysone signaling by its receptor also 
downregulates the expression of miR-14, showing a positive autoregulatory loop, by 
which the alleviation of miR-14-mediated repression of the receptor amplifies the 
response (Varghese and Cohen, 2007).  
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The miR-278 locus was identified in a similar gain-of-function screen for genes 
affecting tissue growth during Drosophila development. miR-278 mutants have elevated 
insulin production and elevated circulating sugar levels, an evidence of insulin-resistance. 
miR-278 acts through regulation of the expanded transcript and this transcript was mostly 
elevated in miR-278 mutants (Teleman et al, 2006). In vertebrates, miR-375 is 
specifically expressed in the pancreatic islet β-cells and suppresses glucose-induced 
insulin secretion (Poy et al, 2004). The myotrophin was experimentally verified as a 




1.7.2 miRNAs in myogenesis and cardiogenesis 
 
miR-1 and miR-133, which are included in the same bicistronic unit, are 
specifically expressed in skeletal muscles and cardiac myocytes (Chen et al, 2006). 
Notably, these two miRNAs differ in their seed sequences and have distinct functions. 
miR-1 plays a key role in skeletal myoblast differentiation by targeting histone 
deacetylase 4 (HDAC4), a transcriptional repressor of muscle differentiation. In contrast 
to miR-1, miR-133 promotes myoblast proliferation by repressing serum response factor. 
Further studies showed miR-133 to be involved in determining cardiomyocyte 
hypertrophy, where overexpression of miR-133 in cardiac myocytes inhibited cardiac 
hypertrophy and inhibition of miR-133 induced hypertrophy. The identified targets of 
miR-133 include: RhoA, a GDP-GTP exchange protein regulating cardiac hypertrophy; 
Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a 
nuclear factor involved in cardiogenesis (Care et al, 2007). 
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miR-181 is expressed at very low levels in adult muscles as compared to miR-1 
and miR-133, but this miRNA is strongly upregulated during myoblast differentiation and 
inhibits the expression of HoxA11, which is a repressor of differentiation (Naguibneva et 
al, 2006). miR-181 is shown to act upstream of MyoD, which induces myogenin that 
triggers the entire differentiation program, including the induction of miR-1 and miR-133. 
Hence miR-181 might be involved in establishing a muscle phenotype, while miR-1 and 
miR-133 are involved in muscle maintenance (Kloosterman et al, 2006). 
 
 
1.7.3 miRNAs in various cancers 
 
Because miRNAs down-regulate target mRNA genes, oncogene targets with 
mutations in the miRNA-complementary sites might escape miRNA regulation to 
generate dominant activating oncogene mutations. miRNAs that are over-expressed or 
amplified in tumors would suggest that these miRNAs negatively regulate tumor 
suppressor or pro-apoptotic genes. Similarly, deleted or down-regulated miRNAs in 
tumors would suggest that such miRNAs target anti-apoptotic or proliferative genes 
(Ruvkun, 2006). Expression analyses have been done on various cancers to identify 
specific miRNAs and their targets (Table 1.2). However, such studies alone do not 
discriminate between whether the miRNAs are induced in cancer, or occur as a result of 
amplification or deletion of the chromosomes. The findings that miRNAs have a role in 
human cancer is also supported by the fact that more than 50% of miRNA genes are 
located at chromosomal regions, such as fragile sites, and regions of deletion or 





Table 1.2. Expression of miRNAs in various tumors.  




Tumor Type Reference 
miR-15a, 
miR-16-1 
Low Bcl-2 Chronic lymphocytic 
leukemia 
Cimmino et al, 
2005 
miR-17-5p High E2F1 Lung, breast, colon, 
pancreas, prostate 
O’Donnell et al, 
2005 
Volinia et al, 2006  
miR-20a High E2F1 Lung, colon, pancreas, 
prostate 
O’Donnell et al, 
2005 
Volinia et al, 2006 
miR-19a High PTEN  Lewis et al, 2003 




colon, lung, pancreas, 
prostate, stomach, liver 
Chan et al, 2005 
Volinia et al, 2006 
Meng et al, 2007 
Zhu et al, 2007 
miR-106a High RB1 Colon, pancreas, 
prostate 
Volinia et al, 2006 
miR-143, 
miR-145 
Low  Colon, B-cells Michael et al, 
2003 
Akao et al, 2007 
Let-7 Low Ras Lung Takamizawa et al, 
2004 




Calin’s group first made the connection between miRNA and cancer. In chronic 
lymphocytic leukemia (CLL), characterized by predominantly non-dividing malignant B 
cells over-expressing the anti-apoptotic B cell lymphoma 2 (Bcl-2) protein, miR-15a and 
miR-16-1, a cluster located at chromosome 13, were found to be deleted or down-
regulated in the majority of CLLs and inversely correlated to Bcl-2 expression, and both 
miRNAs were found to negatively regulate Bcl-2 at a post-transcriptional level (Calin et 
al, 2002). Bcl-2 repression by these miRNAs induced apoptosis in a leukemic cell line 
model (Cimmino et al, 2005). Therefore miR-15 and miR-16 functioned as tumor 
suppressors targeting Bcl-2 to prevent uncontrolled cell growth. 
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Another miRNA with tumor suppressor properties is let-7. Let-7 is down-
regulated in human lung carcinomas and over-expression of let-7 in A549 lung 
adenocarcinoma cell line inhibited lung cancer cell growth in vitro (Takamizawa et al, 
2004). Johnson’s group later showed that let-7 controls the expression of the critical 
human oncogene Ras (Johnson et al, 2005).  
Amplification and over-expresssion of the miRNA cluster mir-17 – 92 at 
chromosomal region 13q31.3 has been reported on various tumors, including lymphoma, 
lung, breast, colon, pancreas and prostate (Hayashita et al, 2005; Volinia et al, 2005). c-
Myc and E2F3 activate expression of the miRNA cluster mir-17 – 92 on human 
chromosome 13, and the expression of the transcription factor E2F1 is negatively 
regulated by two miRNAs in this cluster, miR-17-5p and miR-20a. Further studies on 
miR-20a showed that it targets E2F2 and E2F3 too, to a lesser degree than that for E2F1 
(Sylvestre et al, 2007). These findings revealed a mechanism where c-Myc 
simultaneously activates E2F1 transcription and limits its translation, allowing a tightly 
controlled proliferative signal (O’Donnell et al, 2005; Woods et al, 2007). Although 
E2F1 can promote cell proliferation by transcriptionally activating the S-phase genes, it 
also has the ability to promote apoptosis through the ARF-p53 pathway. miR-19, as part 
of this cluster, has also been found to downregulate the tumor suppressor PTEN 
(phosphatase and tensin homolog deleted on chromosome 10) (Lewis et al, 2003). This 
would lead to promoting the PI3K-Akt pathway, a known survival-promoting signal. It is 
therefore possible that suppression of many target mRNAs by this cluster combine to 
promote cell survival (Hammond, 2006). This is shown when enforced expression of the 
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mir-17-92 cluster in a Eµ-myc mouse strain accelerated formation of B-cell lymphomas 
in the mouse (He et al, 2005). 
In human glioblastoma tumor tissues and cell lines, miR-21 has been found to be 
strongly over-expressed. Knockdown of miR-21 in cultured glioblastoma cells triggers 
activation of caspases and leads to increased apoptotic cell death (Chan et al, 2005). 
Further studies on the knockdown of miR-21 identified the tumor suppressor 
tropomyosin 1 as a target of miR-21 (Zhu et al, 2007). A study on hepatocellular 
carcinoma also showed miR-21 to be highly overexpressed, and targets PTEN (Meng et 
al, 2007).  
 
1.7.4 miRNAs and cell cycle regulation 
 
During development and adulthood, normal cells can tightly control cell 
proliferation, differentiation and death by means of the cell cycle, thereby preventing 
malignant transformation (Liu et al, 2007). The activity of many genes known to control 
cellular proliferation is regulated by cell cycle-dependent oscillation of gene transcription, 
stability (of transcripts and proteins), protein activation (by post-translational 
modification) and protein sequestration (Whitfield et al, 2002).  
The cell cycle is divided into four phases in the order of G1, S, G2 and M phase. 
In G1 phase the diploid cell has 2n chromosomes and starts to prepare for DNA synthesis 
(Schafer, 1998). In the subsequent S phase, DNA duplication occurs and at the end of the 
phase the cell has 4n chromosomes. The cell then continues into the G2 phase and is 
growing to prepare for cell division. During mitosis (M phase), the cell seperates into two 
daughter cells. The transition between the cell cycle phases are controlled mainly by 
complexes containing cyclins and the cyclin-dependent kinases (CDKs). The activities of 
 18 
CDKs are regulated by their interacting partners and phosphorylation on their threonine 
and tyrosine residues. Growth factors stimulate the entry of cells into the cell cycle from 
G0 by the expression of cyclin D, which complex with CDK4 or CDK6 to phosphorylate 
the retinoblastoma protein (pRb). Hypophosphorylated pRb binds the E2F transcription 
factor, preventing the interaction of E2F with DNA. Once pRb is phosphorylated by 
cyclin D-CDK4, pRb releases E2F, allowing it to transcribe proteins necessary for cell 
cycle progression, including cyclin E and cyclin A (Arroyo and Raychaudhuri, 1992).  
Cyclin E and cyclin A complex with CDK2 to promote G1 and S phase progression. 
Cyclin B interacts with CDK1 during late G2 and M phase to allow cell division (Schafer, 
1998). 
Recent evidences suggest that several miRNAs target transcripts that encode 
proteins directly or indirectly involved in cell cycle progression. Moreover, alteration of 
miRNA levels can contribute to pathological conditions, including tumorigenesis as 
mentioned earlier, that are associated with loss of cell cycle control. Hatfield et al 
reported that Drosophila melanogaster germline stem cells mutants for dicer-1 exhibited 
normal stem cell identity but were defective in cell cycle control. The dicer-1 mutant 
germline stem cells were delayed in the G1 to S transition, which is dependent on the 
CDK inhibitor Dacapo (a homologue of the p21/p27 family of CDK inhibitors), 
suggesting that miRNAs are required for stem cells to bypass the normal G1/S 
checkpoint (Hatfield et al, 2005). 
Cellular differentiation is achieved by the coordinated regulation of cell cycle exit, 
activation of lineage-specific gene expression, and in some cases, cell cycle re-entry. 
Peschle and colleagues demonstrated that in hematopoietic progenitor cells, the robust 
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expression of miR-221 and miR-222, clustered on the X chromosome, is markedly 
reduced as cells differentiate into erythroblasts. Cultured erythropoietic cells undergoing 
exponential growth exhibited a reduction in miR-221/222 expression that inversely 
correlated with an increase in protein but not mRNA expression for stem cell factor 
receptor Kit, which is required for survival, proliferation and differentiation of erythoid 
progenitors. Kit was then shown to be a target of miR-221/222 (Felli et al, 2005). Over-
expression of miR-221 or miR-222 accelerated erythropoiesis and impaired cell 
proliferation, with an accompanying increase in the percent of late erythroblasts. Taken 
together, these results support a role for miR-221 and miR-222 in modulating 
erythropoiesis through regulation of Kit (Carleton et al, 2007).  
The progressive transformation of normal cells to malignant ones is driven by 
activation of oncogenes and/or inactivation of tumor suppressors. These genetic 
alterations contribute to the loss of cell cycle control, increased proliferative capacity and 
resistance to senescence and apoptosis characteristic of transformed cells. The alterations 
in miRNA levels in tumors as described earlier may reflect the less differentiated state of 
tumors or indicate that miRNAs causally affect the transformed phenotype (Carleton et al, 
2007).  
Recent studies have shown that changes in miRNA levels in tumors also affect 
cell cycle-related targets, hence contributing to the tumorigenesis. miR-221 and miR-222 
have been found to be up-regulated in human prostate carcinoma cell lines, human 
thyroid papillary carcinomas and human hepatocellular carcinoma, in comparison to their 
normal tissues. The up-regulation was inversely related to that of the cell cycle inhibitor 
p27kip1. p27kip1 was shown to be targeted by miR-221 and miR-222 at two sites on its 
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3’UTR. Over-expression of miR-221 and miR-222 in both types of tumors down-
regulated p27kip1 protein expression and induced a G1 to S shift in the cell cycle, 
consistent with the role of  p27kip1 as an inhibitor to CDK4 and CDK6 that cause the 
transition of cells from G1 to S phase (Galardi et al, 2007; Visone et al, 2007; Fornari et 
al, 2008).  
The let-7 miRNA controls the timing of cell cycle exit and terminal differentiation 
in C. elegans and is poorly expressed or deleted in human lung tumors as described 
earlier (Takamizawa et al, 2004). Over-expression of let-7 in cancer cell lines alters cell 
cycle progression and reduces cell division, and it has been shown that multiple genes 
involved in cell cycle and cell division functions are also directly or indirectly repressed 
by let-7, for example, the Ras oncogene, CDK6 and cell division cycle 25 homolog A 
(CDC25A) (an activator of CDK2, CDK4 and CDK6 by removing the phosphate groups 
on them) (Johnson et al, 2007). 
Another recent study on a family of miRNAs sharing seed region identity with 
miR-16 showed their involvement in directly regulating cell cycle progression and 
proliferation by controlling the G1 checkpoint. In cultured human tumor cells that had 
homozygous disruption of the Dicer helicase domain to cause increased Dicer activity, 
over-expression of miR-16 family of miRNAs led to induction of G0/G1 arrest. Many 
miR-16 targets were identified whose repression could induce G0/G1 accumulation, 
including CDK6 and CDC27, a component of the anaphase-promoting complex that 
regulates mitosis and G1 phase of the cell cycle (Linsley et al, 2007). The simultaneous 
silencing of these target genes may cooperate to control cell cycle progression. 
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The miR-34 miRNA family comprises three highly conserved miRNAs (miR-34a, 
miR-34b and miR-34c). Recently, miR-34 family members were shown to be directly 
regulated by the tumor suppressor, p53, functioning downstream of the p53 pathway as 
tumor suppressors (Corney et al, 2007; He et al, 2007). Deletion of the miR-34a has also 
been associated with MYCN-amplified neuroblastoma, and the over-expression of miR-
34a in several neuroblastoma cell lines induced growth arrest followed by apoptosis 
(Welch et al, 2007). Over-expression of each of the miR-34 family members caused cell 
cycle arrest at G1 in other tumor cell lines and down-regulation of a significant number 
of cell cycle genes like CDK4, cyclin E2, MET (hepatocyte growth factor receptor) and 
E2F3 (He et al, 2007; Welch et al, 2007). From all these studies, as with let-7 and miR-
16 family of miRNAs, miR-34 miRNAs may regulate cell cycle through the simultaneous 
silencing of multiple targets. 
 
1.8 CELL CYCLE REGULATION OF miRNA ACTIVITY 
 
If miRNAs control the highly orchestrated patterns of gene expression that occur 
during cell cycle progression, it seems likely that the cell may also control the activity of 
miRNAs during the cell cycle. It is possible that expression of some miRNAs oscillate 
during the cell cycle, although no reports have yet described this possibility (Carleton et 
al, 2007). Alternatively, miRNAs might be regulated by transcription factors involved in 
cell cycle. A clear example is the induction of miR-17-92 cluster by E2F3 and c-Myc 
(Woods et al, 2007; O’Donnell et al, 2005). 
Cell cycle-dependent regulations in the stability and subcellular localization of 
miRNAs have been reported. Hwang and colleagues examined the expression of miR-29a 
and miR-29b and described how miR-29b is rapidly degraded in cycling cells and can 
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only be stabilized when cells enter or are arrested in mitosis. They also demonstrated that 
a hexanucleotide terminal motif within miR-29b serves as a cis-acting nuclear 
localization sequence, directing miR-29b to the nucleus during interphase (Hwang et al, 
2007). While the function of miR-29b and any role it may have in regulating cell cycle 
progression remains undescribed, these data raise the interesting possibility that cell 
cycle-dependent regulation of miRNA stability may serve to control miRNA function 
(Carleton et al, 2007). 
Intracellular trafficking of miRNAs may also regulate their activity during the cell 
cycle. P-bodies, as described earlier, were thought to be a location for mRNA storage, 
degradation, and sites for RISC activity. In addition, actively proliferating mammalian 
cells had much larger and elevated numbers of P-bodies than quiescent cells. The 
increase in P-body number and size in proliferating cells reached a maximum in G2 and 
was followed by disassembly of P-bodies prior to mitosis with reassembly occurring in 
early G1 (Yang et al, 2004). Translation repression was also found to be strongest at the 
S/G2 phase with miminal repression in the G1 phase, based on a study on luciferase 
reporters bearing miRNA target sites in their 3’UTR (Vasudevan et al, 2008). Disruption 
of P-bodies impaired siRNA and miRNA-mediated gene silencing, although effects on 
cell cycle progression were not reported (Jakymiw et al, 2005; Liu et al, 2005; Rehwinkel 
et al, 2005). These data raise the possibility that the activity of miRNAs in proliferating 
cells may be modulated by cell cycle dependent regulation of P-body dynamics (Carleton 






2 AIMS OF THIS STUDY 
 
Proper regulation of the cell division cycle is crucial to the growth and 
development of all organisms, and understanding this regulation is central to the study of 
many diseases, including cancer. This study aimed to characterize the expressions and 
functions of various miRNAs in cell cycle regulation, using hepatocellular carcinoma cell 
lines. This will help to identify specific miRNAs that oscillate during the cell cycle 
phases. These cell lines will also be used as in vitro models to study the effects of over-
expression or knock-down of miRNAs on cell proliferation, cell cycle control, and to 
identify the cell cycle-regulated proteins targeted by these miRNAs (Figure 2.1). 
 
Figure 2.1. Flow chart showing the study approach to identify specific miRNAs involved 
in cell cycle progression. 
 
HuH7, HepG2 cells were synchronized at various cell 
cycle stages (G1, S, G2/M) 
RNA extraction for real-time PCR of 339 mature miRNAs 
MTS (cell proliferation assay) on cells transfected with miRNA 
mimics or inhibitors 
Further studies for effect of miRNA over-expression or inhibition on cell proliferation 
(apoptosis or delay in proliferation) 
Target identification (Luciferase assay & Western blot) 
Select miRNAs differentially expressed for further study 
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HepG2 cells (hepatocellular carcinoma) were purchased from American Type 
Culture Collection (Manassas, USA). HuH-7 cells (hepatocelllular carcinoma) were 
obtained from RIKEN Bioresource Center (Japan). Dulbecco’s modified Eagle’s medium 
(DMEM), thymidine, hydroxyurea and nocodazole were purchased from Sigma (St. 
Louis, Mo.). All other cell culture reagents, Opti-MEM I reduced serum medium and 
Trizol Reagent were obtained from Gibco (Grand Island, N. Y.). Lipofectamine 2000 was 
purchased from Invitrogen (California, USA). The series of miRNA mimics and 
inhibitors and their fluorescein-labelled ones were obtained from Dharmacon (NYSE: 
TMO). 3-(4,5-dimethylthiazol-2-yl)–5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium/phenazine ethosulfate (MTS/PES) reagent (supplied as Cell Titer 96® 
AQueous One Solution Cell Proliferation Assay), pRL-CMV vector and Dual-Luciferase 
Reporter Assay System were purchased from Promega (Madison, Wis.). Vectashield 
mounting medium was obtained from Vector Laboratories (Burlingame, Calif.). The 
TaqMan MicroRNA Assays Human Panel – Early Access Kit, TaqMan microRNA 
Individual Assay , TaqMan Reverse Transcription Kit and TaqMan Universal PCR 
Master Mix without AmpErase UNG was obtained from Applied Biosystems (Foster City, 
Calif.). The primers and probes used for Reverse transcription and Real-Time PCR of 5S 
rRNA were synthesized by Proligo (Singapore). pMIR-REPORTTM (miRNA Expression 
Reporter Vector) was obtained from Ambion (USA). Anti-actin mouse monoclonal 
antibody was obtained from Calbiochem. Anti-Yes mouse monoclonal antibody and anti-
cyclin c rabbit polyclonal antibody were obtained from BD Transduction Laboratories. 
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Halt Protease Inhibitor Single-Use Cocktail and SuperSignal West Pico Mouse IgG 
Detection Kit were obtained from Pierce, (NYSE: TMO). 
 
3.2 CELL CULTURE 
 
HuH7 and HepG2 cells were grown separately in complete growth medium 
consisting of DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 
100 µg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 0.1 mM MEM 
non-essential amino acids. The cells were cultured at 37 oC in a humified atmosphere of 
5% CO2. 
 
3.3 SYNCHRONISATION OF CELLS 
 
HuH7 cells were synchronized in G1 phase 24 hours after refreshing medium 
from 4mM thymidine block treatment with complete medium. To synchronise cells at S 
phase, thymidine double-block was performed by incubating HuH7 cells in thymidine for 
24 hours followed by a 16-hour recovery in normal complete medium and a second 24-
hour incubation with thymidine; or alternatively treated with 2.5 mM hydroxyurea in 
complete medium for 48 hours. To synchronise cells at metaphase, nocodazole-induced 
blockade was performed by treating HuH7 cells and HepG2 cells with 1 ug/ml 
nocodazole in complete medium for 24 hours and followed by a mitotic shake-off, and 
the suspended cells were collected. HepG2 cells were synchronized in G1 phase by 
incubating mitotic shake-off cells for 4 hours in complete medium. To synchronise cells 
at S phase, thymidine-hydroxyurea double block was performed by incubating HepG2 
cells in thymidine for 24 hours followed by a 16-hour recovery in normal complete 
medium, followed by a 24-hour incubation with hydroxyurea. 
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3.4 CELL CYCLE ANALYSIS 
 
Cells synchronized at G1 or S phase were harvested from 25cm2 tissue-culture 
flasks by trypsinization, while cells synchronized at G2/M phase were harvested by 
mitotic shake-off. All cells harvested were centrifuged, fixed with ice-cold 70% ethanol 
for at least 2 hours, washed with phosphate-buffered saline (PBS), and re-suspended in 
0.4 ml of PBS containing 0.1% Triton-X, 20 ug/ml propidium iodide and 0.2 mg/ml 
RNase A. After a final incubation at 37oC for at least 30 min, cells were analyzed using a 
FACSCanto II flow cytometer (Becton Dickinson). A total of 10,000 events were counted 
for each sample. Data were analyzed using WinMDI 2.8 software. 
 
3.5 RNA EXTRACTION AND QUANTITATION 
 
Total RNA was extracted from the synchronised cells using Trizol Reagent 
(Gibco) according to the manufacturer’s protocol. Briefly, the cells harvested were 
incubated with Trizol Reagent for 1 minute. 0.2 ml of chloroform per ml Trizol was then 
added to the sample. The tube was shaken vigorously by hand for 15 seconds and 
incubated for 5 minutes at room temperature. The tube was then centrifuged at 12,000 x g 
for 15 minutes at 4 oC. Following centrifugation, the mixture was separated into a lower 
red, phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. The 
aqueous phase was then transferred to a fresh tube. Total RNA was precipitated by 
mixing with 0.5 ml of isopropyl alcohol per ml of Trizol. The sample was incubated for 
10 minutes at room temperature and then centrifuged at 12,000 x g for 10 minutes at 4 oC. 
The supernatant was then removed and the RNA pellet was washed once with 75% 
ethanol, adding 1 ml of 75% ethanol per ml of Trizol. The sample was vortexed and 
centrifuged at 7,500 x g for 5 minutes at 4 oC. In the last step, the RNA pellet was briefly 
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dried and dissolved in the appropriate amount of RNase-free water. The concentration of 
the total RNA was quantified by the absorbance at 260 nm. The overall quality of an 
RNA preparation was assessed on electrophoresis on a 1.2% denaturing agarose gel.  
 
3.6 MATURE miRNA EXPRESSION PROFILING 
 
TaqMan MicroRNA Assays Human Panel Early Access Kit and TaqMan 
microRNA Individual Assays (Applied Biosystems) were used for mature miRNA 
expression profiling on the synchronized cell lines. The panel contained 157 of the 
known human miRNAs (later reduced to 156 after hsa-miR-124b was classified as a dead 
entry on the Sanger database). Another 183 TaqMan microRNA Individual Assays not on 
the panel were also used as these were produced after the release of the panel and were 
available at the start of this project. The expression of these 339 miRNAs were profiled 
twice independently for each total RNA sample. cDNA was synthesized from total RNA 
using microRNA-specific RT primers contained in the TaqMan MicroRNA Assays 
Human Panel Early Access Kit or the TaqMan microRNA Human Assays in case of 
individual miRNAs (Applied Biosystems). Briefly, single-stranded cDNA was 
synthesized from 10 ng total RNA in 10-μL reaction volume with the TaqMan miRNA 
Reverse Transcription Kit (Applied Biosystems). Each 10-μL reaction contained 1 mM 
dNTPs, 10 U Multiscribe reverse transcriptase, 0.6 U RNase Inhibitor, and 50 nM of 
miR-specific RT primers. The reaction was incubated at 16°C for 30 minutes followed by 
30 minutes at 42°C, and inactivation at 85°C for 5 minutes. 1.5 uL of each generated 
cDNA was amplified by real-time PCR with sequence-specific primers from the TaqMan 
microRNA Assays on an ABI Prism 7300 real-time PCR system (Applied Biosystems). 
PCR reactions included 5 μL 2× Universal PCR Master Mix (No AmpErase UNG), 1 μL 
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each 10× TaqMan MicroRNA Assay Mix and 1.5 μL reverse-transcribed product; they 
were incubated in a 96-well plate at 95°C for 10 minutes, followed by 40 cycles of 95°C 
for 15 seconds and 60°C for 1 minute. For the 5S ribosomal RNA (rRNA) control, 
primers and probe were designed and synthesized by Sigma-Proligo (The Woodlands, TX, 
USA): 5S for: CGCCCGATCTCGTCTGAT; 5S rev: 
GGTCTCCCATCCAAGTACTAACCA; 5S probe: 
TCGGAAGCTAAGCAGGGTCGGGC. The 5S cDNA was diluted 500 times before 
real-time polymerase chain reaction (PCR) was done. The PCR products were detected 
with the Applied Biosystems 7300 Real Time PCR System and analyzed with the Applied 
Biosystems 7300 System SDS software (Applied Biosystems, Foster City, CA, USA). 
Cycle numbers were determined at a threshold reading of 0.2 fluorescence unit. To 
determine the relative quantity of mature miRNAs, ∆Ct method was used with 5S rRNA 
as an internal control. The threshold cycle (Ct) was determined for each miRNA, and the 
relative amount of each miRNA to 5S rRNA was calculated using the equation 2-∆Ct 
where ∆Ct = CTmiRNA – CT5S rRNA. In order to facilitate data presentation, relative gene 
expression was multiplied by 106.   
 
3.7 EFFECTS OF miRNAs ON CELL PROLIFERATION 
 
HuH7 cells (8x103 cells) or HepG2 cells (6x103 cells) were seeded into each well of a 48-
well plate and allowed to recover for 24 hours. Before transfection, the appropriate 
amount of miRNA mimic or inhibitor oligonucleotides (Dharmacon) was diluted with 
Opti-MEM I Reduced Serum Medium in one tube and incubated for 5 minutes at room 
temperature. 1 ul of Lipofectamine2000 was diluted with 100 ul of Opti-MEM I Reduced 
Serum in another tube and incubated for 5 minutes at room temperature. The two 
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solutions were them mixed equally and incubated for 20 minutes at room temperature to 
allow the miRNA oligonucleotides: Lipofectamine2000 complexes to form. Cells were 
then rinsed with Opti-MEM I Reduced Serum Medium. 200 ul of the miRNA 
oligonucleotide: Lipofectamine2000 complexes was then added to each well in triplicates 
and mixed gently by rocking the plate back and forth. After 4 hours of incubation at 37 
oC in a humified atmosphere of 5% CO2, the transfection reagent was removed and 
replaced with the complete DMEM medium. Mock transfections were carried out for 
both cell lines as described above but with the omission of the miRNA oligonucleotides. 
After 72 hours post-transfection, cell viability assay was performed using CellTitre 96 
AQueous One Solution Cell Proliferation Assay (Promega). 10 µl of the MTS dye was 
added per 100 µl medium, followed by incubation for an hour, and the absorbance at 490 
nm was measured. Similarly, for the small interfering RNA (siRNA)-mediated target 
knockdown, siRNAs for Yes1, MYCN, E2F6 and the negative control (Ambion, Austin, 
TX, USA) were tranfected at 5 - 100 nM for 4 h, after which the transfection reagent was 
removed and replaced with DMEM medium. At 72 h post-transfection, 40 µl of 
MTS/PES reagent was added to each well (Promega, Madison, WI, USA). After 
incubation at 37°C for 1 h, the absorbance at 490 nm was measured. Absorbance values 
reported were normalized against absorbance of treatment medium without cells. All 
assays were performed in triplicates and as two independent experiments. 
 
3.8 EFFECTS OF miRNAs ON CELL CYCLE PROGRESSION 
To analyze the effect of the miRNA oligonucleotides on the cell cycle progression, 
1.3x105 HuH7 cells were seeded in each well of a 6-well plate 24 hours before 
transfection. 24 hours after transfection, the cells were treated with 4mM thymidine for 
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24 hours. The medium containing thymidine was then replaced with fresh complete 
medium for 16 hours before the second 24-hour thymidine block. The cells were released 
from the double thymidine blockade and samples were collected at different time points 
for FACS analysis. 
 
3.9 ESTIMATION OF TRANSFECTION EFFICIENCY 
 
To estimate transfection efficiency, cells were grown on glass slides with 
detachable wells and transfected with fluorescein-labelled miRNA mimic or inhibitor 
negative controls (Dharmacon). 5 hours after transfection, cells were washed twice with 
ice-cold phosphate-buffered saline (PBS), and fixed with chilled methanol (-20oC) for 10 
minutes. The cells were then washed again with PBS and a drop of Vectashield mounting 
media containing propidium idodide was then added. The cells were observed using the 
Leica DMLB fluorescent microscope. The percentage of fluorescein-labelled cells in five 
randomly selected fields from two independent experiments was determined. 
 
3.10 miRNA TARGET PREDICTIONS AND CLONING OF LUCIFERASE 
CONSTRUCTS 
3.10.1 Reverse-transcription-PCR of target sites 
Predicted targets for miR-193a or miR-210 and their target sites were analyzed 
using miRanda, TargetScan, and PicTar. Their expression was detected via reverse 
transcription-PCR (RT-PCR). RT-PCR was performed using Access RT-PCR Kit 
(Promega, USA). The reactions were carried out according to the manufacturer’s protocol. 
Briefly, each 50 µl reaction contained 1.0 µg of RNA, 0.2 mM dNTPs, 0.2 µM of the 
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forward and corresponding reverse primers, 1 mM of MgSO4, 0.1 u/µl of AMV reverse 
transcriptase and 0.1 u/µl of Tfl DNA polymerase. 
Reverse transcription was carried out at 48 oC for 45 min followed by a 
denaturation step at 94 oC for 2 min. Following reverse transcription, the cDNA was 
subjected directly to 35 cycles of PCR as follows: denaturation at 94 oC for 1 min, 
annealing at 55 oC for 30 s and extension at 68 oC for 45 s. A final extension at 68 oC was 
carried out for 2 min.  Primers used are listed in Table 3.1. cDNA fragments containing 
the respective 3’UTR target sites were made by reverse transcription-PCR using total 
RNA extracted from HuH7 cells. Primers used are listed in Table 3.2. The pMIR-
luciferase Yes1/3’UTR construct was also used to generate the mutant fragment of 
3’UTR of the Yes1 lacking the seed sequence of the miRNA binding site. 
Table 3.1 Primers used for detection of predicted mRNA transcripts 
Gene Primers 
CCNC 5’- ACAAGATCTGTTGAAGGAGC 
5’- AGCAGCAATCAATCTTGTAT 
CCND2 5’- TGGCAGCTGTCACTCCTCAT 
5’- CGATCATCGACGGTGGGT 
CDC16 5’- ACCTGACAGCACAATATCAC 
5’- TCGTCCTTCAAGTATTTTTC 
CDK10 5’- AGATGAGATTGTCGCACTGA 
5’- TTGACCTGAGCCTCCGAGAA 
E2F1 5’- CAGCTGGACCACCTGATGAAT 
5’- CAATGCTACGAAGGTCCTGACA 
E2F3 5’- GATGGGGTCAGATGGAGAGA 
5’- GAGACACCCTGGCATTGTTT 
E2F6 5’- GGAGCAGGGTCAGACCAGTA 
5’- TCTCAAATGCCATCAGTTGC 
hSNF5 5’- GACGGCGAGTTCTACATGAT 
5’- CTAGAGTCGTGTATCCGTGA 
MYCN 5’- GCTAGACGCTTCTCAAAACT 
5’- CAACGTTTAGCGCTGTCATG 
MCM8 5’- TTCTCTGAAGTTTACAGCGA 
5’- ACACGAACCACTGTCCCTCT 






Table 3.2 Primers used for luciferase constructs (restriction sites which are used for 
cloning are underlined). 


















































3.10.2 Gel extraction and purification of DNA 
The PCR products were resolved by agarose gel electrophoresis to ensure that the 
products were of the correct size. QIAquick Gel Extraction Kit (QIAGEN) was used to 
perform DNA gel extraction and purification. After gel electrophoresis, the DNA 
fragment of interest was excised and weighed. 3 volumes of buffer QG to 1 volume of gel 
slice were applied to dissolve the gel slice. The completely dissolved sample was then 
loaded onto a QIAquick column sitting in a 2-ml collection tube to bind the DNA. The 
 33 
tube was centrifuged at 12,000 x g for 1 minute and the flow-through was discarded. 0.75 
ml of buffer PE was then added to the column and the tube was centrifuged at 12,000 x g 
for 1 minute twice to allow the buffer PE to flow through completely. The column was 
then placed in a clean 1.5 ml tube. 30 ul of nuclease-free water was added directly onto 
the column to elute the DNA. After standing for 2 minutes at room temperature, the 
column was centrifuged again at 12,000 x g for 1 minute to collect the DNA. 
 
3.10.3 Plasmid construction 
pMIR-REPORT firefly luciferase vector contains the firefly luciferase gene under 
the control of the CMV promoter, with a cloning region downstream of the luciferase 
translation sequence (Figure 3.1). The gel-purified PCR products were digested by their 
respective restriction enzymes (NEB). SpeI and HindIII were used on Cyclin D2, CDC16, 
E2F6, MCM8, N-Myc, Yes1 and hSNF5; and SpeI and MluI were used on CDK10, E2F1, 
E2F3 and Cyclin C. The appropriate corresponding buffer was used for each digestion. 
The digested products were resolved by agarose gel electrophoresis and gel-extracted. 
The purified target products were inserted into the same enzyme-digested pMIR-
REPORT firefly luciferase vector by ligation. The ligated products were transformed into 
competent E.Coli cells of the strain DH5α (Invitrogen). 50 ul of the competent cells were 
added to the ligation products and then allowed to stand on ice for 30 minutes. The 
sample was subjected to heat-shock in 37 oC for 20 seconds and promptly transferred 
back to ice. After 2 minutes, 250 ul of LB (lysogeny broth) was added and the sample 
was incubated at 37 oC with vigorous shaking for 45 minutes. 150 ul of transformed cells 
were then spread on each LB-ampicillin plate and the plates were then incubated 
overnight at 37 oC. 
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Single white colonies were picked and inoculated in 3 ml LB-ampicillin medium 
in loosely capped 15 ml tubes the next day. The cultures were incubated overnight at 37 
oC with vigorous shaking and used for further analysis. Qiagen mini plasmid preparation 
kit was used to extract the plasmid DNA from the bacteria culture. Briefly, the overnight 
bacteria culture was centrifuged at 12,000 x g for 3 minutes and the pellet was re-
suspended in 300 ul of ice-cold buffer P1 by vigorous vortex. 300 ul of buffer P2 was 
then added and the tube was immediately inverted 5 times to mix. Following 5 minutes of 
incubation at room temperature, 300 ul of ice-cold buffer P3 was added and the tube was 
then inverted 5 times rapidly to mix. After 5 minutes of incubation on ice, the tube was 
centrifuged at 14,000 x g for 5 minutes and the supernatant was transferred to a Qiagen-
tip 20 column that had been equilibrated with 1 ml of buffer QBT in advance and was 
allowed to flow through the column by gravity. The column was then washed 4 times 
with 1 ml of buffer QC each time and the DNA was eluted with 0.8 ml of buffer QF and 
collected in a new tube. The eluted DNA was then precipitated with 0.6 ml isopropanol. 
After vortexing briefly, the tube was centrifuged again. The pellet was rinsed with 1 ml 
of 70% ethanol and centrifuged again. The pellet was then air-dried and re-dissolved in 
30 ul of TE buffer. Restriction digestion followed by agarose gel electrophoresis was 
done to check that the size of the vectors and inserts were correct. 
Invitrogen PureLink HiPure plasmid DNA purification kit was used to perform a 
larger scale plasmid preparation and purification (midi-prep). 1 ml bacteria culture 
carrying the correct plasmid was grown in 90 ml of LB-ampicillin medium at 37 oC with 
vigorous shaking overnight. Bacteria cells were harvested by centrifugation at 4,000 x g 
for 10 minutes on the second day. The cell pellet was re-suspended completely in 4 ml of 
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ice-cold Resuspension Buffer with RNase A by vortex. 4 ml of Lysis Buffer was then 
added and the tube was then inverted 5 times to mix. After 5 minutes of incubation at 
room temperature, 4 ml of Precipitation Buffer was added and the tube was inverted 
several times until the mixture was homogeneous. The tube was then centrifuged at 
13,000 x g for 5 minutes at room temperature. The supernatant was transferred to a 
PureLink HiPure Midi column that had been equilibrated with 10 ml Equilibration Buffer 
in advance and was allowed to flow through the column by gravity. The column was then 
washed twice with 10 ml Wash Buffer each time and the DNA was eluted with 5 ml 
Elution Buffer and collected in a new tube. The eluted DNA was then precipitated with 
3.5 ml isopropanol. The tube was then centrifuged at 16,000 x g for 15 minutes at 4 oC. 
The pellet was rinsed with 3 ml 70% ethanol and centrifuged again. The pellet was then 
air-dried for 10 minutes and dissolved in 50 ul of nuclease-free water. 
The concentration and purity of the plamids were determined by measuring 
absorbance at 260 nm and 280 nm. The plasmids were subjected to appropriate restriction 
enzyme digestion followed by agarose gel electrophoresis analysis and the identity was 
confirmed by DNA sequencing. The remainder plasmids were stored at -20 oC. 
 
3.10.4 DNA sequencing 
BigDye Terminator Cycle Sequencing Ready Reaction Kit (ABI) was used for 
DNA sequencing. A typical 20 ul of sequencing reaction mixture consisted of 4 ul of Big 
Dye, 4 ul of 5x Buffer, 500 ng of plasmid, 1 ul of 100 uM appropriate primer, and 
deionized water to make the reaction volume up to 20 ul. Thermal cycling was carried out 
according to the following program: 25 cycles of denaturation at 96 oC for 30 seconds, 
annealing at 50 oC for 15 seconds and extension at 60 oC for 4 minutes. 3 ul of 3 M 
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sodium acetate, 62.5 ul of 95% ethanol and 14.5 ul of deionized water were used to 
precipitate the sample. After 15 minutes of incubation at room temperature, the sample 
was centrifuged at 12,000 x g for 20 minutes. The supernatant was then carefully 
aspirated and the pellet rinsed with 250 ul of 70% ethanol and centrifuged for 5 minutes. 
The air-dried sample was then sent to the NUMI sequencing lab for sequencing. The 
results were compared to the published sequences on GenBank and confirmed to bear the 
seed sequences for miRNA binding. 
 
Figure 3.1. Map of pMIR-REPORT miRNA Expression Reporter (Ambion).  
  
3.11 LUCIFERASE TARGET ASSAY 
HuH7 cells (7 x 104 cells) were seeded into each well of a 24-well plate and 
allowed to recover for 24 h before transfection. Before transfection, the appropriate 
amount of miRIDIAN miRNA mimics or miRIDIAN miRNA inhibitors (Dharmacon, 
Lafayette, CO, USA) was diluted in 150 µl of Opti-MEM
 
I Reduced Serum Medium. 1.5 
µl of Lipofectamine 2000 was also diluted in 150 µl of Opti-MEM
 
I Reduced Serum 
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Medium. The two solutions were mixed gently and incubated for 20 min at 25oC. Cells 
were then rinsed with the Opti-MEM
 
I Reduced Serum Medium. 300 µl of miRNA 
mimics or inhibitors-Lipofectamine
 
2000 solution was then added to each well and the 
plates were incubated at 37°C for 3 h. Control transfections were carried out with either 
the miRIDIAN miRNA minic or inhibitor negative control (Dharmacon, Lafayette, CO, 
USA) while mock transfections were carried out as described but without any mimics or 
inhibitors. The miRNA mimic or inhibitor was removed 3 h after transfection. The cells 
were then transfected with 25 ng of reporter construct and 2.5 ng of pRL-CMV Renilla 
luciferase control plasmid (Promega, Madison, WI, USA) together with Lipofectamine 
2000. 3 h later, the transfection solution was removed and replaced with DMEM. The 
cells were lysed with the Passive Lysis Buffer 24 h after transfection and assayed for the 
firefly luciferase and the Renilla luciferase activities using the Dual-Luciferase Reporter 
Assay System (Promega, Madison, WI, USA). The firefly luciferase activity was 
normalized to that of the Renilla luciferase activity for each well, and the data was 
expressed as relative luciferase activity. 
 
3.12 WESTERN BLOT ANALYSIS 
 
HuH7 cells were lysed in ice-cold 2% Triton X-100 in PBS containing the Halt 
Protease Inhibitor Single-use Cocktail (Pierce, Rockford, IL, USA). The lysed cells were 
centrifuged at 14,000 rpm at 4 oC for 15 minutes. After that, the supernatant was taken 
out as the samples. The protein concentrations of the lysates were measured using the 
Bio-Rad Protein Assay with bovine serum albumin as the standard. 20μg of protein from 
each lysate was separated on a 8% SDS-PAGE gel and transferred onto nitrocellulose 
membrane. The membranes were blocked for 1 hour in blocking buffer (1x TBS-T with 
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5% non-fat milk), followed by incubation with the respective primary antibodies 
overnight. Two monoclonal antibodies were used to detect Yes1 (610376, BD 
Transduction Laboratories, Lexington, KY, USA) and β-actin (CALBIOCHEM, San 
Diego, CA, USA) at dilutions of 1:10,000 each. A rabbit polyclonal antibody was used to 
detect CCNC (558903 , BD Pharmingen, USA) at dilution of 1: The membranes were 
then washed with 1x Tris-buffered saline/Tween-20 (TBS-T) and then incubated with the 
goat anti-mouse secondary antibody or goat anti-rabbit secondary antibody (Pierce, 
Rockford, IL, USA) for an hour at dilution of 1:7500 or 1: 3750. The bound antibodies 
were visualized by using the SuperSignal West Pico chemiluminescent substrate (Pierce, 
Rockford, IL, USA). The bands were quantified using the Syngene Gbox-HR gel 
documentation system (Syngene, Cambridge, United Kingdom). 
 
3.13 QUANTIFICATION OF YES1 mRNA LEVELS 
 
Reverse transcription followed by real-time PCR was performed to quantitate the 
relative quantities of Yes1 mRNA. 0.2 µg of total RNA was reverse-transcribed using the 
Reverse Transcription System (Promega, Madison, WI, USA) and gene-specific reverse 
primers from Sigma-Proligo (The Woodlands, TX, USA). Real-time PCR amplification 
was done using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA). The Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as a 
normalization control. The following primers were used: Yes1 (forward, 5’-
GGACAAGGATGTTTCGGCGA; reverse, 5’-GATCTCGGTGAATATAGTTC), 




3.14 STATISTICAL ANALYSIS 
 
Results are presented as mean ± standard deviation of triplicates from at least two 
individual experiments. Comparison of the different treatment groups to controls of their 
respective cell lines was carried out using ANOVA followed by a Tukey’s post-hoc test. 
A p-value of <0.05 was considered significant. Significant values are denoted by asterisks 





4.1 SYNCHRONIZATION OF HuH7 AND HepG2 CELLS 
 
To identify specific miRNAs that oscillate during the cell cycle phases, HuH7 
cells and HepG2 cells were subjected to synchronization or arrest by different methods to 
harvest the majority of the cells in each cell cycle phase. Sub-G1 and doublet cell 
populations amounted to less than 10% of the total events read and were gated away 
during flow cytomety. Flow cytometry analysis of the DNA content of the harvested cells 
showed that the unsynchronized HuH7 cells had an average of 58% of the total cell 
population in G1, 15% in S phase, and 27% in G2/M phase (Figure 4.1). HuH7 cells were 
best synchronized at G1 phase at 24 hours after the removal of the single thymidine block, 
with at least 77% of the cells in G1 phase (Figure 4.1). The cells were best synchronized 
at S phase by thymidine double block treatment, with approximately 82% of the cells in 
early S phase (Figure 4.1). Treatment of the HuH7 cells with hydroxyurea also 
synchronized the HuH7 cells at S phase, with approximately 75% of the cells in the S 
phase (Figure 4.1). Treatment of the HuH7 cells with nocodazole arrested approximately 
82% of the cells in the G2/M phase (Figure 4.1). 
 
The unsynchronized HepG2 cells had an average of 69% of the total cell 
population in G1, 11% in S phase, and 20% in G2/M phase (Figure 4.2). The various 
treatments used enriched at least 83% of the total cell population in the respective phases 
(Figure 4.2). 
 




A.      B. 
.  
 







Figure 4.1. Flow cytometry analysis of (A) unsynchronized HuH7 cells, (B) HuH7 cells 
synchronized in G1 phase 24 hours after refreshing medium from thymidine block 
treatment, (C) HuH7 cells arrested in S phase after thymidine double block treatment, (D) 
HuH7 cells arrested in S phase after hydroxyurea treatment, (E) HuH7 cells arrested in 
G2/M phase after nocodazole treatment. The flow analysis data shown is representative 
of at least 3 independent samples for each method of synchronization. 
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Figure 4.2. Flow cytometry analysis of (A) unsynchronized HepG2 cells, (B) HepG2 
cells synchronized in G1 phase 4 hours after mitotic shake-off, (C) HepG2 cells arrested 
in S phase after thymidine – hydroxyurea double block, (D) HepG2 cells arrested in 
G2/M phase after nocodazole treatment. The flow analysis data shown is representative 
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4.2 TOTAL RNA EXTRACTION AND MATURE miRNA EXPRESSION 
PROFILING 
 
Total RNA was extracted from cells that were synchronized in the various cell 
cycle phases as determined by flow cytometry. Figure 4.3 shows the quality of the RNA 
extracted, with two major sharp ribosomal RNA bands of 28S and 18S, indicating the 
integrity of the RNA samples. These RNA samples were then used to examine the 
miRNA expression profile. 
 
 The miRNA expression profile in different cell cycle phases was analyzed 
following reverse transcription-real time PCR. This approach had been shown to be 
robust for the direct quantification of mature miRNA molecules without need for 
additional confirmation of the data obtained (Chen et al, 2005; Bandrés et al, 2006). The 
specific miRNAs that had at least two-fold difference in expression between two adjacent 
phases were considered to be differentially expressed. Of the 339 miRNAs that were 
examined in HuH7 cells, 115 miRNAs were differentially expressed during the cell cycle, 
whereas the majority of the miRNAs were unchanged or not detectable at the various 
phases of the cell cycle (Table 4.1). For HepG2 cells, of the 339 miRNAs that were 
examined, 142 miRNAs were differentially expressed during the cell cycle, and the rest 
of the miRNAs were unchanged or not detectable (Table 4.2). In order to facilitate data 
presentation, the relative quantities of miRNAs that were differentially expressed during 
the cell cycle were median-centered and hieratically clustered in both dimensions and 
then plotted in a heatmap by Cluster 2.0 and TreeView 1.6 (Figure 4.4). Similarities 
between HuH7 and HepG2 cells in the up- and down-regulated miRNAs in various 
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phases were selected for further study to identify putative cell cycle-related targets using 
miRanda, PicTar and TargetScan (Table 4.3, 4.4). These cell cycle-related targets were 
selected based on their physiological functions and/or changes in protein expression 
levels that would coincide with the hypotheses that the differentially expressed miRNAs 
would bind to reduce the translation of the specific targets.  
 
       1      2      3   4 5  6       7      8  9 
   
 
Figure 4.3. Separation of RNA on 1.2% formaldehyde denaturing agarose gel. 1 µg total 
RNA was loaded per lane. Lane 1, HuH7 cells unsynchronized. Lane 2, HuH7 cells 
synchronized in G1 phase 24 hours after refreshing medium from thymidine block 
treatment. Lane 3, HuH7 cells arrested in S phase after thymidine double block treatment. 
Lane 4, HuH7 cells arrested in S phase after hydroxyurea treatment. Lane 5, HuH7 cells 
arrested in G2/M phase after nocodazole treatment. Lane 6, HepG2 cells unsynchronized. 
Lane 7, HepG2 cells synchronized in G1 phase 4 hours after mitotic shake-off. Lane 8, 
HepG2 cells arrested in S phase after thymidine – hydroxyurea double block. Lane 9, 

























Table 4.1. List of 339 miRNAs analysed with TaqMan Real-Time PCR with primers and 
probes from Applied Biosystems on HuH7 cells. The miRNAs labeled with * or # 
represent the less denominant form of the miRNA produced by the same precursor. 
 
126 miRNAs not expressed 
in HuH7 cells. 
98 miRNAs not 
differentially expressed at 
various cell cycle phases in 
HuH7 cells. 
115 miRNAs differentially 
expressed at various cell 








































































































































































































































































































































































Table 4.2. List of 339 miRNAs analysed with TaqMan Real-Time PCR with primers and 
probes from Applied Biosystems on HepG2 cells. 
 
104 miRNAs not expressed 
in HepG2 cells. 
93 miRNAs not 
differentially expressed at 
various cell cycle phases in 
HepG2 cells. 
142 miRNAs differentially 
expressed at various cell 































































































































































































































































































































































Figure 4.4. Heat map of miRNA expression profiling of (A) HuH7 samples synchronized 
at G1, S [Thymidine, Hydroxyurea (HU)] and G2/M (Nocodazole) phases for 115 
miRNAs differentially expressed in HuH7, (B) HepG2 samples synchronized at G1, S 
and G2/M (Nocodazole) phases for 142 miRNAs differentially expressed in HepG2. Data 
obtained by RT-real-time PCR were log-transformed, mean and median-centred, 
normalized and hieratically clustered in both dimensions and then plotted in a heat map 
by Cluster 2.0 and TreeView 1.6. Red represents higher miRNA expression for the 
corresponding cell cycle phase relative to other phases, and green represents lower 
miRNA expression for the corresponding cell cycle phase relative to other phases. 
 
 
Table 4.3. Relative expression of miRNAs in different cell cycle phases in (A) HuH7, (B) 
HepG2 cells. 
A. HuH7 cells 
miRNA G1 S (Thymidine) S (Hydroxyurea) G2/M (Nocodazole) 
26a 6.82 ± 1.30 12.74 ± 0.48 24.15 ± 2.76 15.49 ± 4.59 
30c 2.40 ± 0.21 4.67 ± 0.70 7.58 ± 1.21 5.80 ± 1.79 
95 0.85 ± 0.03 2.01 ± 1.37 3.13 ± 1.05 1.71 ± 0.57 
96 1.08 ± 0.28 0.93 ± 0.00 1.01 ± 0.00 0.15 ± 0.11 
100 6.68 ± 1.45 22.06 ± 5.46 27.21 ± 0.27 8.85 ± 1.00 
107 0.30 ± 0.04 0.84 ± 0.87 0.47 ± 0.61 0.09 ± 0.06 
122a 0.02 ± 0.00 0.05 ± 0.00 0.07 ± 0.02 0.03 ± 0.02 
125a 10.96 ± 2.67 12.69 ± 3.14 25.03 ± 10.11 22.47 ± 1.59 
126 0.78 ± 0.16 2.03 ± 0.61 2.52 ± 1.48 1.91 ± 1.65 
148a 2.47 ± 1.42 17.85 ± 15.14 16.74 ± 7.15 12.19 ± 12.11 
193a 0.14 ± 0.03 0.06 ± 0.00 0.06 ± 0.04 0.20 ± 0.05 
210 0.36 ± 0.07 0.40 ± 0.15 0.51 ± 0.13 5.47 ± 0.42 
328 0.08 ± 0.05 0.27 ± 0.17 0.64 ± 0.06 1.86 ± 1.65 
  
B. HepG2 cells 
miRNA G1 
S (Thymidine-
Hydroxyurea) G2/M (Nocodazole) 
26a 22.50 ± 12.99 45.81 ± 3.14 42.73 ± 11.50 
30c 29.02 ± 10.43 61.80 ± 42.90 68.32 ± 17.91 
95 0.50 ± 0.02 1.97 ± 1.83 1.78 ± 1.62 
96 0.27 ± 0.26 0.80 ± 0.42 0.06 ± 0.03 
100 38.27 ± 31.25 78.34 ± 70.96 20.00 ± 10.59 
107 1.09 ± 0.14 1.73 ± 1.74 0.43 ± 0.03 
122a 0.002 ± 0.000 0.20 ± 0.00 0.57 ± 0.00 
125a 14.46 ± 4.93 37.26 ± 31.50 25.03 ± 8.19 
126 0.34 ± 0.08 0.92 ± 0.37 0.89 ± 0.30 
148a 0.41 ± 0.05 1.22 ± 0.96 0.91 ± 0.88 
193a 0.03 ± 0.01 0.99 ± 0.35 2.80 ± 0.44 
210 0.46 ± 0.06 18.20 ± 5.19 15.94 ± 10.18 
328 0.03 ± 0.02 0.28 ± 0.14 0.32 ± 0.24 
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Table 4.4. Predicted cell cycle related targets by miRanda, TargetScan or PicTar for the 
miRNAs differentially expressed. 
miRNA Cell cycle related targets predicted 
miR-26a CDC6, CDK8, CKS2, CDK6, CCNJ, CCND2, YES1 
miR-30c CDC7, CCNK, E2F7, SMARCA5 
miR-95 CDKL3, CCNI 
miR-96 CCNA1, CDC27, CCND2, YES1 
miR-100 CDK7, SMARCA5 
miR-107 CCNE1, CDK6, CCND2 
miR-122a CNNM2, CCNG1, CCNYL1, PAK3, SMARCD1 
miR-125a CCNJ, CNNM1, YES1 
miR-126 CDKN2A, CDKN2AIP 
miR-148a CDC1L6, CDC14A, DTYMK, E2F1 
miR-193a CCNC, CCND2, CDC16, CDK10, E2F1, E2F3, E2F6, SMARCB1, MYCN 
miR-210 MCM8, YES1 
miR-328 CDKN2A, PAK6, SMARCB1 
 
 
4.3 EFFECTS OF miRNAs ON CELL PROLIFERATION 
 
4.3.1 Determination of concentration of miRNA mimics and inhibitors to be used 
 
The effects of the selected miRNAs on cell proliferation were next examined 
through the transient transfection of the miRIDIAN miRNA mimics or miRIDIAN 
miRNA inhibitors in HuH7 and HepG2 cells. As shown in Figure 4.5, the mock 
transfection had no significant effects on the cell proliferation of both cell lines. At 
concentrations up to 100 nM, the mimic negative control (M-neg) had no significant 
effects on the cell proliferation of both cell lines. However, at 75 nM or more, the 
inhibitor negative control (I-neg) caused decreases in cell proliferation of both cell lines. 
Thus, in subsequent experiments, 50 nM of either the miRIDIAN miRNA mimics or 
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Figure 4.5. MTS for transfection of miRIDIAN microRNA Mimic Negative Control CN-
001000-01 (M-Neg), or miRIDIAN microRNA Inhibitor Negative Control IN-001000-01 
(I-Neg), in HuH7 and HepG2 cells. Data shown represent mean + standard deviation 
(n=4). * denotes p<0.05 compared to mock treatment.  
 
 
4.3.2 Transfection efficiency of miRNA mimics and inhibitors 
 
Fluorescein-labeled miRIDIAN miRNA mimic and inhibitor negative controls 
were used to examine the transfection efficiency of these miRNAs used on HuH7 and 
HepG2 cells. At 5 hours after transfection with 50 nM of the labeled negative controls, 
the percentage of fluorescein-labeled HuH7 cells was more than 94% for both the mimic 
and inhibitor negative controls (Figure 4.6), while that for HepG2 cells was only 83% for 
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Figure 4.6. Transfection of fluorescein-labelled miRNA negative controls (green) at 50 
nM. The nucleus was stained with propidium iodide (red). Both signals were 
superimposed, showing the presence of the miRNA negative controls in the cells. A, 
HuH7 cells transfected with miRNA mimic negative control. B, HuH7 cells transfected 
with miRNA inhibitor negative control. C, HepG2 cells transfected with miRNA mimic 
negative control. D, HepG2 cells transfected with miRNA inhibitor negative control. 
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4.3.3 Effects of selected miRNAs on cell proliferation 
 
The 13 miRNAs selected that have differential expression and putative cell cycle-
related targets were examined for their effects on cell proliferation. Treatment of HuH7 
and HepG2 cells with most of the miRNA mimics and inhibitors had no significant effect 
on the cell proliferation, with the exception of miR-193a and miR-210. Over-expression 
of miR-193a and miR-210 in HuH7 cells led to significant inhibition of cell proliferation 
to 40.7±7.0% and 53.6±5.0% respectively, while inhibition of miR-193a and miR-210 led 
to significant increase of cell proliferation to 135.0±7.8% and 145.0±10.8% respectively 
(Figure 4.7A). Similarly, the over-expression of miR-193a and miR-210 in HepG2 cells 
led to significant inhibition of cell proliferation to 41.0±11.0% and 68.9±7.4% 
respectively, but the inhibition of these two miRNAs had no significant effects on the cell 
proliferation (Figure 4.7B). Reduction in cell proliferation was also observed in HuH7 
cells transfected with miR-122a inhibitor, and in HepG2 cells transfected with miR-96 





























































































 HuH7 HepG2 
% Average Average 
Treatment Mimic Inhibitor Mimic Inhibitor 
cells only 112.26 112.90 
mock 100.00 100.00 
Negative control 97.38 91.98 86.13 74.64 
miR-96 104.19 127.27 68.80 82.33 
miR-107 80.62 74.03 108.15 64.65 
miR-122a 90.01 49.48 66.52 49.50 
miR-193a 40.74 135.03 41.03 94.31 
miR-210 53.61 145.03 68.92 95.19 
 
Figure 4.7. MTS for transfection of miRNA mimics and inhibitors in (A) HuH7 and (B) 
HepG2 cells. Data shown represent mean + standard deviation (n=4). * denotes p<0.05 
compared to mock treatment. C, percentage of mock treatment of the miRNAs with effect 
on the MTS assay. 
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4.3.4 Effects of miR-193a and miR-210 on cell cycle progression 
 
miR-193a and miR-210 were selected for further study as consistent changes were 
observed for the over-expression studies for both HepG2 and HuH7 cells. In addition, the 
inhibition studies in HuH7 cells showed consistent enhanced proliferation. Therefore 
work was subsequently carried out using HuH7 cells. Analysis of the HuH7 cells 
overexpressing miR-193a or miR-210 by flow cytometry did not show any significant 
increase in apoptosis (Figure 4.8). To elucidate the mechanism involved in the decrease in 
cell proliferation by miR-193a and miR-210, HuH7 cells over-expressed with miR-193a 
or miR-210 were synchronized by double thymidine block in late G1 phase. The cells 
were released from the block by washing away the thymidine and replacing with fresh 
medium to allow cells to enter into S phase and resume cell cycle progression. Cells 
treated with the miRNA mimic negative control entered G2/M phase by 12 h (Figure 4.8). 
In contrast, cells transfected with miR-193a or miR-210 took a longer time to reach the 
G2/M phase. Taken together, these data indicate that over-expression of miR-193a or 





















      G1 S G2/M 
    cells only 65.3 15.7 17.8 
    M-neg 79.5 12.2 7.1 
  T=0  193a-M 76.5 6.7 15.7 
    210-M 72.2 10.0 17.9 
    M-neg 59.3 30.0 9.2 
  T=4  193a-M 70.6 13.2 15.2 
    210-M 65.1 17.8 17.1 
    M-neg 24.4 59.5 14.6 
  T=6  193a-M 67.1 13.3 16.7 
    210-M 54.9 28.1 16.9 
    M-neg 13.4 32.6 48.7 
  T=9  193a-M 64.1 11.3 22.9 
    210-M 46.0 35.5 18.5 
    M-neg 11.5 21.0 66.8 
  T=12  193a-M 63.4 8.0 26.5 
    210-M 41.9 37.9 20.2 
 
Figure 4.8. Transfection of mimic miR-193a and mimic miR-210 delays HuH7 cell cycle 
progression. A, HuH7 cells were transfected with either mimic negative control (M-neg) 
or mimic miR-193a (193a-M) or miR-210 (210-M). 4 hours after transfection, the cells 
were treated with 4 mM thymidine for 24 hours. The medium containing thymidine was 
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then replaced with fresh complete medium for 16 hours before the second 24-hour 
thymidine block. The cells were released from the double thymidine block and samples 
were collected for FACS analysis at T=0, 4, 6, 9 and 12 hours after release. B, percentage 
of total cell cycle population in each phase.  
 
 
4.4 SCREENING OF PREDICTED TARGETS OF miR-210 
 
To identify putative targets of miR-210 that are involved in cell cycle, a search of 
the miRanda, TargetScan and PicTar was carried out. We focused on MCM8 and Yes1 as 
miR-210 targets (Table 4.5). Both transcripts were found to be expressed in the 
unsynchronized HuH7 RNA samples (Figure 4.9).  
 
We performed luciferase assays with vectors containing these 3’-UTR target sites 
downstream of the luciferase reporter gene (Figure 4.10A). It was observed that in the 
presence of mimic miR-210, the relative luciferase activity was significantly reduced 
only for the Yes1/3’UTR construct but not for the MCM8/3’UTR construct (Figure 
4.10A). As a control, no reduction was observed with the Yes1/3’UTR mutant construct 
with deletions in the seed sequence of the miRNA binding site (Figure 4.10A). Further 
analysis was also carried out to determine whether miR-210 regulates the expression of 
Yes1 protein. Over-expression of miR-210 in HuH7 cells led to reduced expression of 
Yes1 (Figure 4.10B). During the different phases of the cell cycle of HuH7 cells, Yes1 
protein expression was reduced at G2/M phase (Figure 4.10C). This change in Yes1 
expression is similar to that described by Park et al (1995). To determine whether altered 
rates of Yes1 mRNA synthesis contributed to the decreased levels of Yes1 protein, we 
measured the Yes1 mRNA expression of HuH7 cells in the different cell cycle phases by 
real-time PCR. The mRNA levels of Yes1 did not change significantly between S and 
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G2/M phase (Figure 4.11). Hence, Yes1 is found to be a target of miR-210, and the 
decreased protein levels of Yes1 during mitosis appeared to be due to the increase in 
miR-210 that repressed the translation of Yes1 in HuH7 cells.  
 
To test whether the silencing of Yes1 protein by miR-210 contributes to inhibiting 
cell proliferation, Yes1 in HuH7 cells was knocked down by siRNA targeting the open 
reading frame of Yes1, and the cell proliferation was significantly inhibited to 
70.8%±7.5% (Figure 4.12). 
 
 
Table 4.5. Genes targeted by miR-210 as predicted by miRanda. 
Gene Genbank 
sequence 
Score Energy Start End Alignment 
MCM8 NM_032485 15.9458 -25.95 2958 2979 agucggcgacaGUGUGCGUGUC 
           ::||||||||| 
gaagatatgcgTGCACGCACAG 
YES1 NM_005433 14.5813 -20.51 1859 1880 aGUCGGCGACAGUGUGCGUGUc 
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Figure 4.9. Expression of predicted targets of miR-210 detected by RT-PCR in 






































































































Figure 4.10. Regulation of the 3’UTR of Yes1 by miR-210. A, HuH7 cells were 
transfected with miRIDIAN microRNA Mimic Negative Control CN-001000-01 (M-
Neg), or microRNA-210 Mimic (210-M), or miRIDIAN microRNA Inhibitor Negative 
Control IN-001000-01 (I-Neg), or microRNA-210 Inhibitor (210-I). This was followed 






luciferase control plasmid. After 24 h, the cells were lysed and the lysates were assayed 
for the firefly luciferase and the Renilla luciferase activities. The firefly luciferase 
activity was normalized to that of the Renilla luciferase activity for each lysate. Data 
shown represent mean ± SD. All assays were performed in triplicate and as two 
independent experiments.*p<0.05, ANOVA analysis, for comparison between the mimic 
or inhibitor transfected cells and the corresponding control. B, Western blot analysis of 
Yes1 protein expression (top panel) in HuH7 cells treated with only Lipofectamine 2000 
(Mock), or miRIDIAN microRNA Mimic Negative Control CN-001000-01 (M-Neg), or 
microRNA-210 Mimic (210-M), or miRIDIAN microRNA Inhibitor Negative Control 
IN-001000-01 (I-Neg), or microRNA-210 Inhibitor (210-I). β-actin was used as a loading 
control (bottom panel). Yes1 expression was normalized to that of β-actin and the fold 
change was determined by comparison with the levels in mock transfected cells. C, 
Western blot analysis of Yes1 protein expression (top panel) in HuH7 cells in different 





Figure 4.11. Expression of Yes1 mRNA in different cell cycle phases in HuH7 cells 
compared to unsynchronized HuH7 cells (control). Error bars represent standard 

























Figure 4.12. Yes1 is required for HuH7 cell proliferation. HuH7 cells were transfected 
with either siRNA negative control or siRNA targeting Yes1 (siY) at 5 nM. Data shown 





4.5 SCREENING OF PREDICTED TARGETS OF miR-193a 
 
To identify putative targets of miR-193a that are involved in cell cycle, a search of 
the miRanda, TargetScan and PicTar was carried out. We focused on cyclin C (CCNC), 
cyclin D2 (CCND2), CDC16, CDK10, E2F1, E2F3, E2F6, hSNF5 and MYCN as 
putative miR-193a targets (Table 4.6). The transcripts of all these putative targets were 
found to be expressed in the unsynchronized HuH7 RNA samples (Figure 4.13). 
 
We performed luciferase assays with vectors containing these 3’-UTR target sites 
downstream of the luciferase reporter gene (Figure 4.14A). It was observed that in the 
presence of mimic miR-193a, the relative luciferase activity was significantly reduced 
only for the CCNC/3’UTR, E2F6/3’UTR and MYCN/3’UTR constructs. Further analysis 
was also carried out to determine whether miR-193a regulate the expression of cyclin C, 
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E2F6 and MYCN. Although the transcript of MYCN and E2F6 was detected, MYCN and 
E2F6 proteins could not be detected, despite trying several different antibodies. The over-
expression or inhibition of miR-193a did not result in any significant changes in the 
levels of cyclin C protein (Figure 4.14B). To test whether the silencing of MYCN or 
E2F6 protein by miR-193a contributes to inhibiting cell proliferation, these two proteins 
in HuH7 cells were knocked down by siRNAs targeting the open reading frames of 
MYCN or E2F6. The cell proliferation was significantly inhibited to 67.3%±6.0% only 
for MYCN (Figure 4.15). 
 
 
Table 4.6. Genes targeted by miR-193a as predicted by miRanda/TargetScan/PicTar 
Gene Genbank sequence Start End Alignment 
CCNC NM_005190 2023 2044 ugacccugaAACAUCCGGUCAA 
         ||  ||||||||| 
acaatcaggTTTCAGGCCAGTT 
CCND2 NM_001759 1776 1795 CUG------CGGUCAA 
|||      ||||||| 
GAT------GCCAGTT 
CDC16 NM_001078645 2085 2106 UGACCCUGAAACAUCCGGUCAa 
||||   |  ||||||::||| 
ACTGTCCCAGTGTAGGTTAGTa 
CDK10 NM_052988 847 867 UGACCCUGAAACAUCCGGUCAa 
:|||  || | || ||||||| 
GCTGCCAC-TGGTCGGCCAGTa 
E2F1 NM_005225 2241 2261 gacccugaaaCAUCCGGUCAA 
          | :|||||||| 
gccctctccaGGGGGCCAGTT 
E2F3 NM_001949 3482 3488 ------CGGUCAA 
      ||||||| 
------GCCAGTT 
E2F6 NM_198256 1251 1273     GACCCUGAAACAUCCGGUCAA 
       ||        |||||||  
CAGTAGCGGCATCAT—-GGCCAGTA 
hSNF5 NM_003073 1636 1656 gacccugaaacaUCCGGUCAa 
            :|||:||| 
gagccccaggcaGGGCTAGTa 
MYCN NM_005378 2144 2165 ugaCCCUGAAACAUCCGGUCAa 
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Figure 4.13. Expression of predicted targets of miR-193a detected by RT-PCR in 
unsynchronized HuH7 cells. Lane M, 100 bp ladder. Lane 1, CCNC. 2, CCND2. 3, 











































































































































Fold    1.0    0.8    1.1   0.9  0.8 
 
 
Figure 4.14.  Screening of predicted targets of miR-193a. A, HuH7 cells were transfected 
with miRIDIAN microRNA Mimic Negative Control CN-001000-01 (M-Neg), or 






IN-001000-01 (I-Neg), or microRNA-193a Inhibitor (193a-I). This was followed by 
transfection with the respective reporter constructs and the pRL-CMV Renilla luciferase 
control plasmid. After 24 h, the cells were lysed and the lysates were assayed for the 
firefly luciferase and the Renilla luciferase activities. The firefly luciferase activity was 
normalized to that of the Renilla luciferase activity for each lysate. Data shown represent 
mean ± SD. All assays were performed in triplicate and as two independent 
experiments.*p<0.05, ANOVA analysis, for comparison between the mimic or inhibitor 
transfected cells and the corresponding control. B, Western blot analysis of CCNC 
protein expression (top panel) in HuH7 cells treated with only Lipofectamine 2000 
(Mock), or miRIDIAN microRNA Mimic Negative Control CN-001000-01 (M-Neg), or 
microRNA-193a Mimic (193a-M), or miRIDIAN microRNA Inhibitor Negative Control 
IN-001000-01 (I-Neg), or microRNA-193a Inhibitor (193a-I). β-actin was used as a 
loading control (bottom panel). CCNC expression was normalized to that of β-actin and 



























Figure 4.15. Knockdown of MYCN reduces HuH7 cell proliferation. HuH7 cells were 
transfected with either siRNA negative control or siRNA targeting MYCN (siNM) or 
E2F6 (siE) at 100 nM. Data shown represent mean + standard deviation (n=4). * denotes 
p<0.05 compared to mock treatment. 
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5.  DISCUSSION 
 
5.1 DIFFERENTIAL EXPRESSION OF miRNAs DURING CELL CYCLE 
PHASES 
 
In this study, the change in the expression of miRNAs during the progression of 
cell cycle was examined. Exponentially growing cell cultures are generally asynchronous, 
each cell progresses through the cell cycle independently of the cell cycle stage of its 
neighbouring cells. In order to follow the expression of miRNAs during the progression 
of the cell cycle, the cell lines were synchronized by various methods to obtain enriched 
populations of cells at a single cell cycle phase. Mitotic shake-off is one of the oldest and 
perhaps easiest methods for obtaining mitotically enriched populations of cells. This 
method is based on the observation that as cells progress into metaphase during mitosis 
they become rounded and have fewer points of attachment with the culture vessel 
(Merrill, 1998). However, this procedure was not applicable to the HuH7 cell line, as the 
mitotic cells still remained strongly attached to the culture vessel. Serum starvation, a 
method of enriching cells at the G0/G1 phase by starving the cells of external growth 
factors found in the serum of the medium used (Merrill, 1998), was also not applicable to 
both cell lines as both lines are capable of secreting its own growth factors to stimulate 
their cell cycle progression. Hence, in order to obtain a high percentage of cells at the 
specific cell cycle phases, different chemicals were used. The mitotic cells from both cell 
lines were enriched by nocodazole arrest. Nocodazole chemically interferes with the 
organization of microtubules in cells. Microtubule formation is required for the 
condensation of chromatin and alignment on the metaphase plate; hence the use of 
nocodazole arrests cells in a prophase to pseudo-metaphase state (Merrill, 1998). 
Hydroxyurea and high concentrations of thymidine prevent replication by inhibiting 
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ribonucleotide reductase, thus starving the cells of the deoxycytidine triphosphate needed 
for DNA polymerization, causing cells to arrest at the S-phase (Merrill, 1998).  
The miRNA expression profiles based on 339 miRNAs led to the identification of 
more than 100 different miRNAs that are differentially expressed. These miRNAs are 
specifically up- or down-regulated at G1, S or G2/M phase. The expression of these 
miRNAs could be regulated during the cell cycle at the level of transcription. The 
difference in the miRNA expression profiles between HuH7 and HepG2 cells in general 
may be a result of the status of p53 expression in the two lines. The p53 in HepG2 cell 
line is wild-type, while the p53 in HuH7 cell line has a point mutation in the DNA-
binding domain of the p53 protein, resulting in its decreased transcriptional activity (Hsu 
et al, 1993; Hailfinger et al, 2007). Similar mutations in p53 have been reported to 
contribute to liver cancer development (Staib et al, 2003). 
The miRNAs with similarities between HuH7 and HepG2 cells in the up- and 
down-regulated expression in various phases were selected for further study to identify 
putative cell cycle-related targets using miRanda, PicTar and TargetScan (Table 4.5, 4.6). 
These cell cycle-related targets were selected based on their physiological functions 
and/or reported changes in protein expression levels that would coincide with the 
hypotheses that the differentially expressed miRNAs would bind to reduce the translation 
of the specific targets. These putative targets include cell division cycle proteins (CDCs), 
cyclins, CDKs, inhibitors of CDKs, proteins required for DNA replication (MCM8), the 
E2F family of transcription factors, and proteins involved in signaling to promote cell 
proliferation.  
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In order to identify the roles of the differentially expressed miRNAs and their 
corresponding targets, the selected miRNAs were either over-expressed through the 
transfection of synthetic oligonucleotides that mimic miRNAs, or inhibited through the 
transfection of synthetic oligonucleotides that are anti-sense to the miRNAs, and any 
changes in cell proliferation were observed using the MTS assay. The MTS assay reflects 
the number of viable cells through the production of NADPH or NADH by 
dehydrogenase enzymes in metabolically active cells. 11 of the 13 selected miRNAs that 
had no significant effects on cell proliferation based on the MTS assay were sieved out, 
resulting in the selection of miR-193a and miR-210 to be further studied, both of which 




5.2 ROLE OF miR-210 IN CELL CYCLE 
 
 
In this study, miR-210 was found to be up-regulated in the G2/M phase in HuH7 
cells. The over-expression of miR-210 was found to inhibit cell proliferation by delaying 
cell cycle progression. In addition, inhibition of miR-210 showed consistent enhanced 
cell proliferation. MCM8 and Yes1 were identified as putative targets of miR-210.  
MCM8 (minichromosome maintenance complex component 8) is a MCM2-7 
related protein that functions as a DNA helicase in unwinding during replication and 
elongation (Maiorano et al, 2005). Hence, it is possible that the up-regulation of miR-210 
in G2/M phase reduces the protein expression of MCM8 during G2/M phase as the DNA 
replication would have been completed and MCM8 would not be needed. However, 
results from the luciferase reporter assay indicate that there is no binding of miR-210 to 
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the predicted binding site on the 3’UTR of MCM8. This false positive could be due to the 
inadequacies in the target prediction principles used by miRanda, as the complementarity 
between miR-210 and MCM8 only occurs at position 1-9 from the 5’ end of miR-210, 
with no other pairing on the 3’ end of miR-210. 
Yes1 is a member of the Src family of non-receptor tyrosine kinases. The Yes 
kinase was discovered as the cellular homologue of the oncogenic v-yes (Yoshida et al, 
1980; Sukegawa et al, 1987). The Yes1 gene encodes a 62 kDa non-receptor tyrosine 
kinase that is expressed across a wide range of normal cells and tissues (Sudol and 
Hanafusa, 1986). Yes1 has been implicated in various signaling pathways that regulate a 
vast array of cellular processes, including cytokine and growth factor responses, 
cytoskeleton dynamics, cell proliferation, survival and differentiation (Summy et al, 2003; 
Clump et al, 2005). The Yes1 protein expression and enzyme activity were also reported 
to be reduced during the G2/M phase (Park and Cartwright, 1995). Hence, it is possible 
that the up-regulation of miR-210 in G2/M phase reduces the protein expression Yes1 in 
G2/M phase. Results from the luciferase reporter assay showed that the over-expression 
of mR-210 significantly reduced the luciferase activity of the Yes1/3’UTR construct, and 
this reduction appears to be due to the binding of miR-210 to the predicted binding site 
on the 3’UTR of Yes1, as no reduction was observed with the Yes1/3’UTR mutant 
construct with deletion in the seed sequence of the miR-210 binding site. In HuH7 cells, 
over-expression of miR-210 also significantly reduced the levels of Yes1 protein. 
Consistent with these findings, there were no significant changes in the mRNA levels of 
Yes1 between S and G2/M phase, but the protein expression of Yes1 was reduced at 
G2/M phase while miR-210 expression is up-regulated. Hence, Yes1 is found to be a 
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target of miR-210, and the decreased protein levels of Yes1 during mitosis appeared to be 
due to the increase in miR-210 that repressed the translation of Yes1 in HuH7 cells. The 
delay in cell cycle progression when miR-210 is over-expressed may be attributed to the 
reduction of Yes1 translation, as cell proliferation of HuH7 cells was also reduced when 
Yes1 was knocked down with siRNA targeting the open reading frame of the Yes1 
transcript. Similar knockdown studies of Yes1 by siRNA in human retinal microvascular 
endothelial cells showed decreased VEGF-induced cell proliferation, with no changes in 
the DNA fragmentation (Werdich and Penn, 2005). Hence, Yes1 might serve to relay 
mitogenic signals and result in promoting cell cycle progression in the G1 and S phases, 
and the up-regulation of miR-210 in the G2/M phase serves to repress the translation of 
Yes1 as cells enter the G2/M phase. 
Using MatInspector, a bioinformatics software that predicts promoter elements, 
the region upstream of miR-210 gene was found to have several consensus binding sites 
for CCAAT, E2F and cell cycle dependent element (CDE) (Figure 5.1). The presence of 
these elements on the promoter region of miR-210 is similar to that of genes that are 
activated at the G2/M phase such as cyclin B. This could explain the repression of miR-
210 at G1 and S phases and increased expression at the G2/M phase, since these elements 
have been shown to be important in repressing cyclin B expression during G1 and 
activating it during G2/M phase (Fung and Poon, 2005). However, none of the putative 
cell cycle dependent transcription factors for the miR-210 gene were predicted as targets 
of miR-210 by miRanda, TargetScan or PicTar. 
In previous studies of miRNA expression in various cancers, some groups have 
reported the higher expression of miR-210 in breast cancer (Camps et al, 2008; Iorio et al, 
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2005; Volinia et al, 2006). In contrast, gene copy loss of miR-210 was observed in 
epithelial ovarian cancer and melanoma cancer (Giannakakis et al, 2008; Zhang et al, 
2006). Recent studies have reported that miR-210 could be induced by hypoxia-inducible 
factor (HIF-1α) during hypoxia, a condition of decrease in the oxygen concentration that 
often occurs as a consequence of the growth of malignant tumors (Kulshreshtha et al, 
2007; Camps et al, 2008; Giannakakis et al, 2008; Pulkkinen et al, 2008). Hence, the 
expression of miR-210 in cancers could be determined by its gene copy number and 
whether the tumors were hypoxic. E2F3, a key protein in cell cycle, has been confirmed 
as a target of miR-210 (Giannakakis et al, 2008). The loss of miR-210 in cancer could 
cause increase in E2F3 expression, while hypoxic induction of miR-210 could cause 
decrease in E2F3 expression. Interestingly, hypoxia is also a strong inducer of vascular 
endothelial growth factor (VEGF), and miR-210 was also predicted to target VEGF (Hua 
et al, 2006). The induction of both VEGF and miR-210 under hypoxia could provide a 
regulated control of the protein expression of VEGF, at the same time controlling c-Yes 
expression, such that growth of cells under hypoxia is controlled. miR-210 was also 
shown to potentially regulate neuronal pentraxin 1 and ephrin-A3. These two proteins are 
expressed in adult brain, with ephrin-A3 inhibiting the growth of neuritis during 
development, and neuronal pentraxin 1 mediating hypoxia injuries in primary cortical 
neurons (Stein et al, 1999; Gao et al, 2000; Hossain et al, 2004). However, these two 
proteins are up-regulated during hypoxia, so it still remains to be determine if and how 





Figure 5.1. Schematic of cyclin B1, miR-210 and miR-193a promoters indicating E2F 
binding sites, CDE binding sites, CCAAT elements, and CHR (cell cycle genes 
homology region) elements. All elements are identified based on previous studies (Zhu et 
al, 2004; Tommasi and Pfeifer, 1995; Zwicker et al, 1995a; Yun et al, 1999; Wasner et al, 
2003) for cyclin B1, and MatInspector analysis for miR-210 and miR-193a.  
 
 
5.3 ROLE OF miR-193a IN CELL CYCLE 
 
In this study, miR-193a was found to be up-regulated in G2/M phase of both 
HuH7 and HepG2 cells. The over-expression of miR-193a was found to inhibit cell 
proliferation by delaying cell cycle progression. In addition, inhibition of miR-193a 
showed consistent enhanced cell proliferation in HuH7 cells. HepG2 cells did not have 
similar enhanced cell proliferation upon inhibition of miR-193a, even though the 
transfection efficiency of the miRNA inhibitor negative control was high at 90% for 












HepG2. This may be due to the HepG2 cells being at the maximal rate of proliferation 
and cannot grow any faster. Cyclin C, cyclin D2, CDC16, CDK10, E2F1, E2F3, E2F6, 
SMARCB1 and MYCN were identified as putative targets of miR-193a.  
Cyclin C has been described to complex with CDK3 and phosphorylate pRb in 
quiescent cells to allow the transition of quiescent cells from G0 to G1 phase (Ren and 
Rollins, 2004). Cyclin C can also complex with CDK8 to regulate the activity of RNA 
polymerase II and control transcription (Akoulitchev et al, 2000). Results from the 
luciferase reporter assay showed that the over-expression of miR-193a significantly 
reduced the luciferase activity of the CCNC/3’UTR construct. However, there were no 
significant differences in the protein levels of cyclin C between miR-193a mimic and 
control transfections. This showed that cyclin C may not be a functional target of miR-
193a. This observation could also be due to the high levels of existing cyclin C proteins 
that remain present even if there is reduced translation of the transcript over the course of 
the experiment. It would then be unlikely for miR-193a to reduce the amount of cyclin C 
proteins during the short cell cycle duration. 
Cyclin D2, like other D-type cyclins, complex with CDK4 or CDK6 to 
phosphorylate pRb and release E2F from the hyperphosphorylated pRb, allowing E2F to 
transcribe proteins necessary for cell cycle progression (Sherr and Roberts, 1999). Hence, 
it was possible that the up-regulation of miR-193a in G2/M phase could reduce the 
protein expression of cyclin D2 during G2/M phase, and thus reduce its association with 
CDK4 or CDK6 and allow pRb to be dephosphorylated by PP1 (Ludlow et al, 1993). 
However, results from the luciferase reporter assay indicate that there is no binding of 
miR-193a to the predicted binding site on the 3’UTR of cyclin D2. This false positive 
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could be due to the inadequacies in the target prediction principles used by PicTar, as the 
complementarity between miR-193a and cyclin D2 only occurs on position 1-7 from the 
5’ end of miR-193a, and the last 3 nucleotides on the 3’ end of miR-193a. 
CDC16 is a subunit of the anaphase-promoting complex (APC) that catalyzes the 
ubiquitination of cell cycle regulators to mark them for proteolysis by the 26S proteasome 
(Harper et al, 2002). Hence, it was possible that the up-regulation of miR-193a in G2/M 
phase could reduce the protein expression of CDC16 during G2/M phase, thus limiting 
the amount of APC complexes available to ubiquitinate and mark their targets for 
proteolysis. However, results from the luciferase reporter assay indicate that there is no 
binding of miR-193a to the predicted binding site on the 3’UTR of CDC16. This false 
positive could be due to the inadequacies in the target prediction principles used by 
miRanda. 
CDK10 is a Cdc2-related kinase that has no known association with any cyclins. 
Two isoforms are derived from the same gene by alternative splicing. One isoform is 
proposed to be involved in the G2/M transition of the cell cycle while the second isoform 
binds to the Ets2 transcription factor and modulates its transactivation activity (Li et al, 
1995; Kasten and Giordano, 2001). Hence, it is possible that the up-regulation of miR-
193a in G2/M phase could reduce the protein expression of CDK10 during G2/M phase, 
thus limiting the amount of CDK10 available to play its role in the G2/M transition. 
However, results from the luciferase reporter assay indicate that there is no binding of 
miR-193a to the predicted binding site on the 3’UTR of CDK10. This false positive again 
highlights the inadequacies of the target prediction principles used by miRanda. 
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E2F1, E2F3 and E2F6 belong to the E2F family of transcription factors that 
regulate genes involved in cell cycle progression (Ren et al, 2002). E2F1 and E2F3 are 
often described as ‘activator’ E2Fs because they transcriptionally activate genes that act 
in the transition from G1 to S phase of the cell cycle (Leone et al, 1999). This subclass of 
E2Fs also has a maximal expression at the late G1 and early S phase (DeGregori and 
Johnson, 2006). E2F6 is a transcriptional repressor and is distinguished by its ability to 
repress E2F target genes at the S phase, thereby distinguishing G1/S and G2/M 
transcription during the cell cycle (Giangrande et al, 2004). The expression of E2F6 
during cell cycle was also reported to be regulated by the activating E2Fs, such that the 
up-regulation of the E2F6 during cell cycle would come after the up-regulation of the 
activating E2Fs in the G1/S phase (Lyons et al, 2006). Results from the luciferase 
reporter assay showed that the over-expression of miR-193a significantly reduced the 
luciferase activity of the E2F6/3’UTR construct but not that for E2F1 and E2F3, showing 
that E2F6 could be a possible target of miR-193a. However, the E2F6 protein was 
undetectable with western blotting, showing that the protein expression could be low in 
the cell lines used. In addition, knockdown of E2F6 by siRNA targeting the open reading 
frame of E2F6 did not affect the cell proliferation of HuH7 cells. Hence, neither over-
expression nor inhibition of miR-193a could make a significant difference to regulating 
the expression of E2F6. It is worthy to note that E2F6 has been recently reported to be a 
target of miR-193a in oral squamous cell carcinoma cell lines, where the authors showed 
down-regulation of E2F6 protein and reduced cell growth upon ectopic expression of 
miR-193a (Kozaki et al, 2008). On the other hand, studies of E2F6-/- mouse embryo 
fibroblasts have no defect in the proliferation ability of these cells, and E2F4, another 
 77 
transcriptional repressor in the E2F family, was shown to compensate for the loss of 
E2F6 (Giangrande et al, 2004). It is possible that the up-regulation of miR-193a in G2/M 
phase might contribute to repressing the translation of E2F6 in the G2/M phase, as an 
additional control in cell cycle, but this effect cannot be used to explain the delay in cell 
cycle progression when there is over-expression of miR-193a. 
SMARCB1 (Snf5) is a subunit of the SWI/SNF chromatin remodeling complex 
that functions to re-position nucleosomes and thereby modulating the accessibility of 
specific genes to the transcriptional machinery. As such, Snf5 has potent tumor 
suppressor activity (Sansam and Roberts, 2006). MYCN is a member of the MYC family 
of transcription factors that is highly amplified in neuroblastomas and is a proto-
oncogene (Brodeur et al, 1985). These two putative targets were also selected for study to 
see whether miR-193a can affect their protein expression levels. Results from the 
luciferase reporter assay showed that the over-expression of miR-193a significantly 
reduced the luciferase activity of the MYCN/3’UTR construct but not that for SMARCB1, 
showing that MYCN could be a possible target of miR-193a. However, the MYCN 
protein was undetectable with western blotting, indicating that the protein expression 
could be low in the cell lines used. Knockdown of MYCN by siRNA targeting the open 
reading frame of MYCN reduced the cell proliferation of HuH7 cells. Interestingly, 
MYCN was also recently reported to be expressed but with no reduction in the MYCN 
protein levels upon over-expression of miR-193a in the oral squamous cell carcinoma cell 
lines (Kozaki et al, 2008). Hence, MYCN may not be a functional target of miR-193a. 
Using MatInspector, the genome region upstream of miR-193a was found to have 
several consensus binding sites for E2F and cell cycle dependent element (CDE) (Figure 
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5.1). The consensus binding sites for CCAAT are further approximately 1.4kb upstream 
of the miR-193a gene and are not indicated on Figure 5.1. The presence of these elements 
on the promoter region of miR-193a is similar to that of genes that are activated at the 
G2/M phase such as cyclin B. This could explain the repression of miR-193a at G1 and S 
phases and increased expression at the G2/M phase, since these elements are important in 
repressing cyclin B expression during G1 and activating it during G2/M phase (Fung and 
Poon, 2005).  
miR-193a has been reported to be frequently down-regulated in oral squamous 
cell carcinoma through aberrant DNA methylation (Kozaki et al, 2008). The authors also 
reported that the ectopic transfection of miR-193a into these cell lines significantly 
reduced cell growth, with down-regulation of E2F6. Over-expression of miR-193a was 
also reported to increase tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
–induced caspase activity in several cell lines (Ovcharenko et al, 2007). Hence, it is 
possible that miR-193a might be associated with cell cycle arrest, indicating a tumor 
suppressor function. 
 
5.4 ROLES OF miR-122a, miR-96 AND miR-107 IN CELL CYCLE 
 
Across the differentially expressed miRNAs selected for further study, the 
transfection of miR-122a, miR-96 and miR-107 also had effects on the cell proliferation, 
although the results were not uniform across both cell lines used. This could be due to the 
differences in expression of the putative targets, such that the presence of a target in one 
cell line and its absence in the other cell line can cause different effects on the 
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proliferation of the cell. More cell lines could be used to determine the trend of the 
effects of the miRNAs.  
The inhibition of miR-122a was observed to decrease cell proliferation of both 
cell lines, but the over-expression of miR-122a also caused a decrease in cell proliferation 
in HepG2 cells. miR-122a is specifically expressed in normal liver but is down-regulated 
in most hepatocellular carcinoma and its derived cell lines (Gramantieri et al, 2007). 
Such expression could suggest the involvement of miR-122a as a suppressor in 
hepatocarcinogenesis, as the over-expression of miR-122a resulted in decrease in cell 
proliferation of HepG2 cells, a hepatocellular carcinoma-derived cell line. Cyclin G1 has 
been shown to be a target of miR-122a (Gramantieri et al, 2007), and it is known to be 
induced by p53 and p73, and act as a negative feedback player by binding to p53 and p73 
and down-regulating their expression, such that the impairment of p53 and p73 by cyclin 
G1 leads to the cancellation of DNA damage-induced cell cycle arrest (Ohtsuka et al, 
2003). 
The over-expression of miR-96 was observed to decrease cell proliferation only in 
HepG2 cells, hence its putative targets should be involved in promoting cell proliferation. 
Computational analysis predicted cyclin A1, cyclin D2, CDC27 and Yes1 as possible cell 
cycle targets of miR-96. Cyclin A1 is mainly expressed in the male germ cells and 
functions in the meiotic cell cycle, hence this may not be a relevant target in the liver cell 
lines HuH7 and HepG2 (Wolgemuth et al, 2004). Cyclin D2 is involved in activating 
CDK4 and CDK6 to allow cells to transit from the G1 to S phase; CDC27 is a component 
of the anaphase-promoting complex (APC/C) that functions to allow cells to exit mitosis 
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(King et al, 1995). Hence, depletion of Yes1, cyclin D2 or CDC27 by miR-96 may cause 
the cells to arrest.  
The inhibition of miR-107 was observed to decrease cell proliferation only in 
HepG2 cells, hence its putative targets should be involved in suppressing cell 
proliferation. Computational analysis predicted cyclin D2, cyclin E1 and CDK6 as 
possible cell cycle targets of miR-107. The inhibition of miR-107 should result in an 
increase in the translation of its targets, but increasing the protein levels of cyclin D2, 
cyclin E1 and CDK6 should not decrease cell proliferation. Hence, these predicted targets 
cannot be used to explain the results from HepG2 cells. To date, reports on miR-107 
indicate that it may regulate targets involved in lipid metabolism, and a study on 
hepatocellular adenoma with under-expression of miR-107 hypothesized that the under-
expression of miR-107 in hepatocellular adenoma may contribute to the steatotic 




In this study, the change in the expression of miRNAs during the progression of 
cell cycle of HuH7 and HepG2 cells was examined. Among the miRNAs that are 
differentially expressed during the cell cycle, miR-193a and miR-210 were found to be 
up-regulated during the G2/M phase. These two miRNAs were also found to decrease 
cell proliferation by delaying cell cycle progression. Upon further study, Yes1, a member 
of the Src family of non-receptor tyrosine kinases, was found to be a target of miR-210. 
The knockdown of Yes1 by siRNA also produced a similar decrease in cell proliferation. 
Hence, the up-regulation of miR-210 in G2/M phase caused the silencing of Yes1 
expression at the G2/M phase, and Yes1 might serve to relay mitogenic signals and result 
in promoting cell cycle progression in the G1 and S phases. miR-122a, miR-96 and miR-
107 were also found to cause changes in cell proliferation, although their changes were 
not uniform between the two cell lines used, and hence not further studied. 
 For further study, it would be interesting to see how the differentially expressed 
miRNAs are regulated at their respective promoter regions. This would give a better 
insight into the role of miRNAs in cell cycle with respect to their cause of expression and 
the relationship with their downstream targets. The understanding of this regulation 
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